
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-id journal-id-type="coden">jmcmar</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">2832868</article-id><article-id pub-id-type="doi">10.1021/jm901788j</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)† </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>McHardy</surname><given-names>Tatiana</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Caldwell</surname><given-names>John J.</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Cheung</surname><given-names>Kwai-Ming</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Hunter</surname><given-names>Lisa J.</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Taylor</surname><given-names>Kevin</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Rowlands</surname><given-names>Martin</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Ruddle</surname><given-names>Ruth</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Henley</surname><given-names>Alan</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>de Haven Brandon</surname><given-names>Alexis</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath10"><name><surname>Valenti</surname><given-names>Melanie</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath11"><name><surname>Davies</surname><given-names>Thomas G.</given-names></name><xref rid="affb" ref-type="aff">§</xref></contrib><contrib contrib-type="author" id="ath12"><name><surname>Fazal</surname><given-names>Lynsey</given-names></name><xref rid="affb" ref-type="aff">§</xref></contrib><contrib contrib-type="author" id="ath13"><name><surname>Seavers</surname><given-names>Lisa</given-names></name><xref rid="affb" ref-type="aff">§</xref></contrib><contrib contrib-type="author" id="ath14"><name><surname>Raynaud</surname><given-names>Florence I.</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath15"><name><surname>Eccles</surname><given-names>Suzanne A.</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath16"><name><surname>Aherne</surname><given-names>G. Wynne</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" id="ath17"><name><surname>Garrett</surname><given-names>Michelle D.</given-names></name><xref rid="affa" ref-type="aff">‡</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath18"><name><surname>Collins</surname><given-names>Ian</given-names></name><xref rid="cor1" ref-type="author-notes">*</xref><xref rid="affa" ref-type="aff">‡</xref></contrib><aff id="affa"><label>‡</label>Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, U.K.</aff><aff id="affb"><label>§</label>Astex Therapeutics Ltd, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, U.K.</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>To whom correspondence should be addressed. Phone <phone>+44 208 722 4317</phone>; Fax <fax>+44 208 722 4126</fax>. E-mail: <email>ian.collins@icr.ac.uk</email>.</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>02</month><year>2010</year></pub-date><pub-date pub-type="ppub"><day>11</day><month>03</month><year>2010</year></pub-date><volume>53</volume><issue>5</issue><fpage>2239</fpage><lpage>2249</lpage><history><date date-type="received"><day>02</day><month>12</month><year>2009</year></date><date date-type="asap"><day>12</day><month>02</month><year>2010</year></date><date date-type="issue-pub"><day>11</day><month>03</month><year>2010</year></date></history><permissions><copyright-statement>Copyright © 2010 American Chemical Society</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>American Chemical Society</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://pubs.acs.org" license-type="open-access"><license-p>This is an open-access article distributed under the ACS AuthorChoice Terms &amp; Conditions.  Any use of this article, must conform to the terms of that license which are available at <uri xlink:href="http://pubs.acs.org">http://pubs.acs.org</uri>.</license-p></license></permissions><abstract><p content-type="toc-graphic"><SecTag type="ABS"><text><SENT sid="1" pm="."><plain> </plain></SENT>
</text></SecTag></p><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Protein kinase B (PKB or Akt) is an important component of intracellular signaling pathways regulating growth and survival. </plain></SENT>
<SENT sid="3" pm="."><plain>Signaling through PKB is frequently deregulated in cancer, and inhibitors of PKB therefore have potential as antitumor agents. </plain></SENT>
<SENT sid="4" pm="."><plain>The optimization of lipophilic substitution within a series of 4-benzyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amines provided ATP-competitive, nanomolar inhibitors with up to 150-fold selectivity for inhibition of PKB over the closely related kinase PKA. </plain></SENT>
<SENT sid="5" pm="."><plain>Although active in cellular assays, compounds containing 4-amino-4-benzylpiperidines underwent metabolism in vivo, leading to rapid clearance and low oral bioavailability. </plain></SENT>
<SENT sid="6" pm="."><plain>Variation of the linker group between the piperidine and the lipophilic substituent identified 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as potent and orally bioavailable inhibitors of PKB. </plain></SENT>
<SENT sid="7" pm="."><plain>Representative compounds modulated biomarkers of signaling through PKB in vivo and strongly inhibited the growth of human tumor xenografts in nude mice at well-tolerated doses. </plain></SENT>
</text></SecTag></p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm901788j</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm-2009-01788j</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="ac1" fn-type="accession-codes"><label>†</label><p><text><SENT sid="8" pm="."><plain>PDB ID Codes: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pdb" xlink:href="2x37">2x37</ext-link> (10-PKB), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pdb" xlink:href="2x39">2x39</ext-link> (21-PKB). </plain></SENT>
</text></p></fn></fn-group></notes></front><body><SecTag type="INTRO"><sec id="sec1"><title><text><SENT sid="9" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="10" pm="."><plain>The serine/threonine protein kinase B (PKB,aaAbbreviations: AGC, cAMP-dependent, cGMP-dependent and protein kinase C; ELISA, enzyme-linked immunosorbent assay; mTOR, mammalian target of rapamycin; PH, pleckstrin homology; PKA, protein kinase A; PKB, protein kinase B; PI3K, phosphatidylinositol-3 kinase; PI(3,4,5)P3, phosphatidylinositol-3,4,5 triphosphate; PTEN, phosphatase and tensin homologue. also known as Akt) plays an important role in signaling within cells, promoting both cell proliferation and survival.(1) PKB is a key downstream component in the phosphatidylinositol-3 kinase (PI3K) signaling pathway.(2) The binding of extracellular growth factors to tyrosine receptor kinases at the cell surface leads to activation of PI3K, which in turn produces phosphatidylinositol-3,4,5 triphosphate (PI(3,4,5)P3) anchored to the inner side of the plasma membrane. </plain></SENT>
<SENT sid="11" pm="."><plain>Binding of PKB to PI-3,4,5-P3 through the pleckstrin homology (PH) domain of the enzyme promotes activation of the kinase by phosphorylation on Ser473 and Thr308.3,4 Activated PKB signals through phosphorylation of several enzyme or transcription factor substrates, including GSK3β, FKHRL1, BAD, and mTOR, to promote proliferation, protein translation, progression through the cell cycle, and antiapoptotic survival.1,2 </plain></SENT>
</text></p><p><text><SENT sid="12" pm="."><plain>Unregulated signaling in the PI3K−PKB−mTOR pathway is a common molecular pathology in many human cancers.(5) PKB itself is overexpressed or activated in several cancers, such as prostate, breast, and ovarian carcinomas, and PKB is therefore an attractive target for cancer therapy.6−10 Efforts in targeting PKB have increased in recent years, and a number of inhibitor chemotypes with well-defined interaction to the protein have been described in the literature.7−10 These cover a range of mechanisms from ATP- or substrate-competitive inhibition through to allosteric modulation of kinase activity. </plain></SENT>
<SENT sid="13" pm="."><plain>Several classes of ATP-competitive small molecule inhibitors of PKB have been described, including pyridines,(11) azepanes,(12) indazole-4,7-diones,(13) isoquinoline-5-sulfonamides,(14) 6-phenylpurines,(15) 4-phenylpyrazoles,(16) pyrrolo[2,3-d]pyrimidines,17,18 thiophenecarboxamides,(19) and aminofurazans.(20) However, only a limited number of chemotypes have been reported to have entered early phase clinical trials, including the aminofurazan 1 (GSK690693)(21) (Figure 1). </plain></SENT>
<SENT sid="14" pm="."><plain>A challenge in the development of selective ATP-competitive inhibitors of PKB has been the extensive conservation of the ATP binding sites of the AGC kinase family.(22) An alternative approach to achieve highly selective inhibition of PKB has been developed using ATP noncompetitive inhibitors that target an allosteric site between the kinase and PH-domains of the enzyme.7,8,23,24 An allosteric PKB inhibitor is in clinical development.(25) </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig1" position="float"><label>Figure 1</label><caption><p><text><SENT sid="15" pm="."><plain>Structures of the ATP-competitive inhibitors 1 and 2. </plain></SENT>
</text></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2009-01788j_0011" id="gr1" position="float"/></fig></SecTag><p><text><SENT sid="16" pm="."><plain>Our laboratory has previously reported the development of a hit from fragment screening15,16 into 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine 2 (CCT128930) (Figure 1), a potent ATP-competitive inhibitor of PKBβ. </plain></SENT>
<SENT sid="17" pm="."><plain>Crucially, 2 also showed inhibition of relevant molecular biomarkers in the PI3K−PKB−mTOR pathway in cells.(17) This compound was 28-fold selective for PKB compared to the structurally homologous kinase PKA and showed good overall selectivity for PKB and other AGC kinases in a wider kinome profile. </plain></SENT>
<SENT sid="18" pm="."><plain>Although the selectivity and cellular potency of 2 were sufficient to merit investigation of its in vivo profile, the compound had high clearance in vivo and low oral bioavailability. </plain></SENT>
<SENT sid="19" pm="."><plain>In this article, we describe modifications to 2 leading initially to compounds with higher selectivity for PKB and ultimately to the identification of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective and orally bioavailable inhibitors of PKB with in vivo antitumor activity. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS,DISCUSS"><sec id="sec2"><title><text><SENT sid="20" pm="."><plain>Results and Discussion </plain></SENT>
</text></title><p><text><SENT sid="21" pm="."><plain>The design of ATP-competitive inhibitors selective for PKB against PKA is challenging because these enzymes are very closely related with high sequence homology in the ATP-binding site (∼80%).(22) X-ray crystallographic analysis of the modes of binding of 2 in PKA and a PKA-PKB chimeric protein representative of PKB(26) suggested that 2 exhibited productive binding of the chlorobenzyl group within a lipophilic pocket formed by P-loop residues in PKB.(17) However, in PKA, the presence of a single amino acid difference (Met282 PKB, Leu173 PKA) in the ribose binding site resulted in a change of conformation of the bound ligand, directing the lipophilic 4-chlorobenzyl group into a less favorable, solvent exposed region. </plain></SENT>
<SENT sid="22" pm="."><plain>On the basis of this explanation for the observed selectivity of 2, we attempted the synthesis of a wider range of substituted analogues to investigate if higher selectivity could be obtained (Table 1). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title><text><SENT sid="23" pm="."><plain>Inhibition of PKBβ and PKA by Substituted 4-Benzyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amines </plain></SENT>
</text></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2009-01788j_0001" id="fx1" position="float"/><table-wrap-foot><fn id="t1fn1"><label>a</label><p><text><SENT sid="24" pm="."><plain>Inhibition of PKBβ kinase activity in a radiometric filter binding assay,(17) single determination. </plain></SENT>
<SENT sid="25" pm="."><plain>Standard inhibitor N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline sulfonamide (H-89) gave mean IC50 (±SD) = 590 (±220) nM (n = 20). </plain></SENT>
</text></p></fn><fn id="t1fn2"><label>b</label><p><text><SENT sid="26" pm="."><plain>Inhibition of PKA kinase activity in a radiometric filter binding assay,(16) single determination. </plain></SENT>
<SENT sid="27" pm="."><plain>Standard inhibitor N-(2-methylaminoethyl)-5-isoquinoline sulfonamide (H-8) gave mean IC50 (±SD) = 5300 (±2010) nM (n = 14). </plain></SENT>
</text></p></fn><fn id="t1fn3"><label>c</label><p><text><SENT sid="28" pm="."><plain>Ratio of IC50 values (PKA/PKB). </plain></SENT>
</text></p></fn><fn id="t1fn4"><label>d</label><p><text><SENT sid="29" pm="."><plain>Mean (±SD), n = 3 determinations. </plain></SENT>
</text></p></fn><fn id="t1fn5"><label>e</label><p><text><SENT sid="30" pm="."><plain>Mean (±SD), n = 4 determinations. </plain></SENT>
</text></p></fn><fn id="t1fn6"><label>f</label><p><text><SENT sid="31" pm="."><plain>Mean of two determinations, individual values in parentheses. </plain></SENT>
</text></p></fn><fn id="t1fn7"><label>g</label><p><text><SENT sid="32" pm="."><plain>nd = not determined. </plain></SENT>
</text></p></fn><fn id="t1fn8"><label>h</label><p><text><SENT sid="33" pm="."><plain>Mean (±SD), n = 5 determinations. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="34" pm="."><plain>Variation of the substituents on the benzyl group of 2 in general lead to somewhat reduced affinity for PKB. </plain></SENT>
<SENT sid="35" pm="."><plain>Exceptions were the 2,4-dichlorobenzyl and 2-napthyl analogues 12 and 18, respectively, which inhibited PKB with similar potencies to 2. </plain></SENT>
<SENT sid="36" pm="."><plain>An interesting influence of the substituents on the selectivity of the compounds for PKB versus PKA was seen. </plain></SENT>
<SENT sid="37" pm="."><plain>While translocation of the 4-chloro group of 2 to the 3-position (3) reduced both affinity and selectivity, approximately 40-fold selectivity was recovered in the 2-chlorobenzyl analogue 4. </plain></SENT>
<SENT sid="38" pm="."><plain>Replacement with more electron-rich 2-, 3-, or 4-substituents (5−8) gave compounds with selectivities in a similar range (ca. 20−48-fold), although the 2-methoxy analogue 9 was surprisingly less potent at PKB. </plain></SENT>
<SENT sid="39" pm="."><plain>Gratifyingly, combination of the 2- and 4-chloro substituents in the analogue 12 increased the selectivity to ca. </plain></SENT>
<SENT sid="40" pm="."><plain>150-fold while retaining nanomolar potency at PKB. </plain></SENT>
<SENT sid="41" pm="."><plain>The 2,6-dichloro substitution pattern 14 gave similarly high selectivity for PKB, although this was not seen with other dihalobenzyl analogues 13, 15, and 16. </plain></SENT>
<SENT sid="42" pm="."><plain>Introduction of a larger, lipophilic 4-tert-butyl substituent 10 also gave a high selectivity for PKB (ca. </plain></SENT>
<SENT sid="43" pm="."><plain>126-fold). </plain></SENT>
<SENT sid="44" pm="."><plain>An intermediate level of selectivity (ca. </plain></SENT>
<SENT sid="45" pm="."><plain>70-fold) was seen for the 2-napthyl derivative 18. </plain></SENT>
</text></p><p><text><SENT sid="46" pm="."><plain>Where the selectivity of PKB over PKA was increased for the compounds in Table 1, this was due to reduced inhibitory activity against PKA rather than an increase in affinity for PKB and was associated with increased lipophilicity of the benzyl group. </plain></SENT>
<SENT sid="47" pm="."><plain>This structure−activity relationship was broadly consistent with the rationale proposed from the comparison of 2 bound to PKA and PKA-PKB chimera, in which the benzyl substituent interacts poorly with PKA relative to PKB, and is directed toward solvent. </plain></SENT>
<SENT sid="48" pm="."><plain>The ability to bind to PKB was minimally compromised for the analogues with larger substituents. </plain></SENT>
<SENT sid="49" pm="."><plain>The X-ray crystal structure of the PKB-selective analogue 10 bound to PKBβ was determined and showed a very similar binding mode to that of 2(17) (Figure 2). </plain></SENT>
<SENT sid="50" pm="."><plain>The tert-butyl substituent occupied the lipophilic pocket formed by the P-loop of PKB, with the 4-amino substituent interacting with Glu236 and the backbone carbonyl of Glu279 in the ribose pocket. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig2" position="float"><label>Figure 2</label><caption><p><text><SENT sid="51" pm="."><plain>Crystal structures of (A) 10 bound to PKBβ and (B) 21 bound to PKBβ. </plain></SENT>
<SENT sid="52" pm="."><plain>(C) Overlay of the bound conformations of 2 (gold), 10 (green), and 21 (blue). </plain></SENT>
</text></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2009-01788j_0002" id="gr2" position="float"/></fig></SecTag><p><text><SENT sid="53" pm="."><plain>As an alternative to substituent variation in the 4-amino-4-benzylpiperidine series, we also investigated compounds with varied chain length between the 4-aminopiperidine and 4-chlorophenyl groups (Table 2). </plain></SENT>
<SENT sid="54" pm="."><plain>The ether 19 was as potent as 2 against PKB but had no selectivity against PKA, which we speculated was due to the more flexible linker group. </plain></SENT>
<SENT sid="55" pm="."><plain>While the amide 20 had reduced affinity for PKB, the isomeric amide 21 retained activity for PKB and showed some selectivity (ca. </plain></SENT>
<SENT sid="56" pm="."><plain>14-fold) over PKA. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title><text><SENT sid="57" pm="."><plain>Development of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide PKB Inhibitors </plain></SENT>
</text></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2009-01788j_0003" id="fx2" position="float"/><table-wrap-foot><fn id="t2fn1"><label>a</label><p><text><SENT sid="58" pm="."><plain>Inhibition of PKB β kinase activity in a radiometric filter binding assay,(17) single determination. </plain></SENT>
<SENT sid="59" pm="."><plain>Standard inhibitor N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89) gave mean IC50 (±SD) = 590 (±220)nM (n = 20). </plain></SENT>
</text></p></fn><fn id="t2fn2"><label>b</label><p><text><SENT sid="60" pm="."><plain>nd = not determined. </plain></SENT>
</text></p></fn><fn id="t2fn3"><label>c</label><p><text><SENT sid="61" pm="."><plain>Mean (±SD), n = 3 determinations. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="62" pm="."><plain>A set of analogues of the amide 21 were investigated using substituent patterns corresponding to those studied for the 4-amino-4-benzylpiperidines (Table 2). </plain></SENT>
<SENT sid="63" pm="."><plain>Most compounds were potent against PKB, but selectivity was generally decreased against PKA when compared with the 4-benzylpiperidines shown in Table 1. </plain></SENT>
<SENT sid="64" pm="."><plain>Variation of the position of the chlorine atom in the aromatic ring showed that 4-substitution as in 21 was optimal. </plain></SENT>
<SENT sid="65" pm="."><plain>Other 4-substituents (24−27) showed a decrease in PKB inhibitory activity with increasing size, and the 4-tert-butyl analogue 27 in particular was less active than the rest of the analogues in this set. </plain></SENT>
<SENT sid="66" pm="."><plain>This contrasted with the structure−activity relationship seen for the 4-benzylpiperidines, and we ascribed these differences to the presence of the longer and relatively inflexible amide spacer which could result in larger 4-substituents being unable to interact as favorably with PKB. </plain></SENT>
<SENT sid="67" pm="."><plain>As with the 4-benzylpiperidines, the 2,4-dichlorobenzyl amide 28 gave improved selectivity (ca. </plain></SENT>
<SENT sid="68" pm="."><plain>24-fold) for PKB over PKA. </plain></SENT>
<SENT sid="69" pm="."><plain>Other less lipophilic 2,4-dihalobenzyl amides (30−32) retained activity at PKB but with reduced selectivity. </plain></SENT>
<SENT sid="70" pm="."><plain>In some cases, increases in PKA activity for the benzyl amides were seen relative to nonamide comparators. </plain></SENT>
<SENT sid="71" pm="."><plain>Although constrained by the amide, the longer linker will allow the lipophilic substituent to attain a different range of conformations compared to the simple 4-benzylpiperidines (Figure 2), resulting in the recovery of productive contacts to the P-loop of PKA. </plain></SENT>
</text></p><p><text><SENT sid="72" pm="."><plain>Methylation of the amide NH of 21 to give compound 33, and the conformationally constrained tertiary amides 34 and 35, led to loss of potency against PKB. </plain></SENT>
<SENT sid="73" pm="."><plain>The crystal structure of 21 bound to PKBβ showed the inhibitor bound in very similar fashion to 2 and 10, with the 4-amino group forming interactions with Glu236 and the backbone carbonyl of Glu279, while the 4-chlorophenyl ring was located in the P-loop lipophilic pocket (Figure 2B). </plain></SENT>
<SENT sid="74" pm="."><plain>As observed for 2 and 10, the inhibitor’s basic amino group formed a favorable close contact with the sulfur of Met282 (ca. </plain></SENT>
<SENT sid="75" pm="."><plain>3.5 Å), an interaction which is lost in PKA. </plain></SENT>
<SENT sid="76" pm="."><plain>It is possible that the proximity of the electron-rich sulfur residue compensates for loss of hydration of the protonated amine on binding.(17) A possible additional interaction was also observed to the amide spacer of 21 with close approach (ca. </plain></SENT>
<SENT sid="77" pm="."><plain>3.3 Å) of the amide NH in the inhibitor and the side chain of Asp293. </plain></SENT>
<SENT sid="78" pm="."><plain>The 10-fold drop in activity for the N-methyl amide 33 relative to 21 may reflect the disruption of this conformation in that complex. </plain></SENT>
</text></p><p><text><SENT sid="79" pm="."><plain>The effect of substituting the pyrrolo[2,3-d]pyrimidine bicycle by 7-azaindole, oxopurine, and pyrazolo[3,4-b]pyridine was investigated for the most potent and selective piperidine moieties (Table 3). </plain></SENT>
<SENT sid="80" pm="."><plain>The bicyclic heteroaromatic groups form hydrogen bonds to a part of the kinase domain, known as the hinge region, that links the distinct N- and C-terminal lobes. </plain></SENT>
<SENT sid="81" pm="."><plain>7-Azaindole was the original hinge-binding fragment from which this compound series was derived.15,17 The carbonyl functionality of 8-oxopurine was expected to make additional interactions with PKB, particularly the residue Thr213 at the entrance to the hydrophobic pocket of the kinase which differs between PKB and PKA. </plain></SENT>
<SENT sid="82" pm="."><plain>For a similar reason, the pyrazolo[3,4-b]pyridine bicycle was selected to provide an additional polar atom in the ligand in this region. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title><text><SENT sid="83" pm="."><plain>4-Azaindole, 8-Oxopurine, and Pyrazolo[3,4-b]pyridine Hinge Binders Substituted with Selected 4-Aminopiperidines </plain></SENT>
</text></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2009-01788j_0004" id="fx3" position="float"/><table-wrap-foot><fn id="t3fn1"><label>a</label><p><text><SENT sid="84" pm="."><plain>Inhibition of PKBβ kinase activity in a radiometric filter binding assay,(17) single determination. </plain></SENT>
<SENT sid="85" pm="."><plain>Standard inhibitor N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline sulfonamide (H-89) gave mean IC50 (±SD) = 590 (±220) nM (n = 20). </plain></SENT>
</text></p></fn><fn id="t3fn2"><label>b</label><p><text><SENT sid="86" pm="."><plain>Mean of two determinations, individual values in parentheses. </plain></SENT>
</text></p></fn><fn id="t3fn3"><label>c</label><p><text><SENT sid="87" pm="."><plain>nd = not determined. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="88" pm="."><plain>The azaindole 36, the direct analogue of 2, showed similar potency but no selectivity for PKB over PKA. </plain></SENT>
<SENT sid="89" pm="."><plain>The 4-amidopiperidine containing azaindole 38 was also unselective. </plain></SENT>
<SENT sid="90" pm="."><plain>Introduction of the 4-tert-butyl substituent to give 37 increased the selectivity, mirroring the structure−selectivity relationship seen with the pyrrolo[2,3-d]pyrimidines 2 and 27, but only to ca. </plain></SENT>
<SENT sid="91" pm="."><plain>20-fold. </plain></SENT>
<SENT sid="92" pm="."><plain>The 7-azaindoles were therefore associated with generally lower selectivity for PKB over PKA than the pyrrolo[2,3-d]pyrimidines. </plain></SENT>
<SENT sid="93" pm="."><plain>We believe this reduction in selectivity arises from the replacement of a nitrogen (N-3) in the pyrrolo[2,3-d]pyrimidines by a carbon in the azaindoles. </plain></SENT>
<SENT sid="94" pm="."><plain>This changes the preferred conformation and orientation of the piperidine ring relative to the bicycle and thus the vectors of the basic amine and lipophilic substituents. </plain></SENT>
<SENT sid="95" pm="."><plain>Because selectivity in this series arises from efficiently exploiting a single amino acid difference (Leu/Met) between PKA and PKB, selectivity is particularly sensitive to the positioning of the amine group relative to this residue. </plain></SENT>
<SENT sid="96" pm="."><plain>The 8-oxopurines 39−41 offered similar or improved selectivity compared to their pyrrolo[2,3-d]pyrimidine congeners but with somewhat lower potency at PKB. </plain></SENT>
<SENT sid="97" pm="."><plain>On the basis of the binding modes of purine inhibitors in this series,(17) the 8-oxopurine carbonyl group is positioned to accept a hydrogen bond from the side-chain of Thr213. </plain></SENT>
<SENT sid="98" pm="."><plain>Because the equivalent residue is valine in PKA, this would be expected to contribute to selectivity for PKB. </plain></SENT>
<SENT sid="99" pm="."><plain>Targeting this difference in the ATP binding sites of PKB and PKA has been noted to increase the selectivity of other inhibitor chemotypes.(11g) The pyrazolo[3,4-b]pyridine hinge-binding group provided ligands 42 and 43 with intermediate potency and selectivity between the azaindole and pyrrolo[2,3-d]pyrimidine analogues. </plain></SENT>
</text></p><p><text><SENT sid="100" pm="."><plain>The inhibitory profiles of the PKB-selective compounds 2, 10, and 21 were investigated in a wider panel of 22 kinases(27) (Figure 3). </plain></SENT>
<SENT sid="101" pm="."><plain>As previously reported,(17)2 mainly showed activity (&gt;80% at 1uM) against PKB, PKA, and two other enzymes (ROCK2 and p70S6K), all from the AGC kinase subfamily. </plain></SENT>
<SENT sid="102" pm="."><plain>Some activity (40−80% @ 1 μM) was seen against four other kinases in the panel. </plain></SENT>
<SENT sid="103" pm="."><plain>The tert-butyl analogue 10 was remarkably selective, showing significant activity against only two kinases, namely PKB and p70S6K, in this panel. </plain></SENT>
<SENT sid="104" pm="."><plain>The amide 21 had a similar profile to 2, showing some activity (&gt;80% at 1uM) against the same enzymes (PKB, PKA, ROCK2, and p70S6K). </plain></SENT>
<SENT sid="105" pm="."><plain>Lower levels of activity were seen for some other AGC kinases but not for kinases outside this subfamily. </plain></SENT>
<SENT sid="106" pm="."><plain>The pattern of selectivity was reflected in the Gini coefficients for the compounds,(28) which takes into account the total levels of inhibitory activity across the panel, with compound 10 showing a higher overall selectivity (Figure 3). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig3" position="float"><label>Figure 3</label><caption><p><text><SENT sid="107" pm="."><plain>Selectivity profiles and Gini coefficients(28) (G) of 2 (A), 10 (B), and 21 (C) against a panel of 22 human kinases, measured at 1 μM concentration of the test compound. </plain></SENT>
<SENT sid="108" pm="."><plain>Kinase dendrogram(29) reproduced courtesy of Cell SignalingTechnology, Inc. </plain></SENT>
<SENT sid="109" pm="."><plain>(www.cellsignal.com). </plain></SENT>
</text></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2009-01788j_0006" id="gr3" position="float"/></fig></SecTag><p><text><SENT sid="110" pm="."><plain>The antiproliferative activity of selected inhibitors was assessed in the PC3 M human prostate cancer and U87MG glioblastoma human cancer cell lines, which are known to have PTEN deletion and an activated PI3K-PKB pathway30,31 (Table 4). </plain></SENT>
<SENT sid="111" pm="."><plain>A specific readout of targeted PKB inhibition in cells was also obtained by quantifying inhibition of phosphorylation of the downstream substrate GSK3β by cell ELISA.(32) The majority of the compounds were active in the antiproliferative assays, although this assay may sometimes include contributions from off-target activities. </plain></SENT>
<SENT sid="112" pm="."><plain>The more selective pyrrolo[2,3-d]pyrimidines 10 and 12 showed similar potencies in the cellular assays to the lead compound 2. </plain></SENT>
<SENT sid="113" pm="."><plain>The potent but unselective ether-linked analogue 19 was also active, but a fall in antiproliferative activity was observed for the amides 21 and 28 compared to their nonamide counterparts. N-Methylation of the amide in 33 to reduce polarity and increase cell permeability did not substantially improve the cellular activity relative to 21, but the activity of 33 may be compromised by the 3-fold drop in affinity for PKB (Table 2). </plain></SENT>
<SENT sid="114" pm="."><plain>The 7-azaindole analogues 36 and 37 were similar to their pyrrolo[2,3-d]pyrimidine counterparts 2 and 10, while the 7-azaindole 38 was less active in cells than its comparator 21. </plain></SENT>
<SENT sid="115" pm="."><plain>The 8-oxopurine 40 retained similar cellular activity to the analogous pyrrolo[2,3-d]pyrimidine 10. </plain></SENT>
<SENT sid="116" pm="."><plain>The cellular activity of these compounds, which are highly selective for PKB over PKA, and over other kinases in the case of 10, argues for the antiproliferative effects of the inhibitors being primarily driven by inhibition of PKB. </plain></SENT>
<SENT sid="117" pm="."><plain>The 8-oxopurine amide analogue 41 had no activity in the cellular assays despite good PKB affinity. </plain></SENT>
<SENT sid="118" pm="."><plain>It is likely that low cell penetration is encountered for this scaffold, the most polar of those prepared, an effect encountered earlier in the evolution of this series.(17) Better cellular activity was seen for the pyrazolo[3,4-b]pyridines 42 and 43, but these compounds offered no advantage over the activity of 2, 10, and 21. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title><text><SENT sid="119" pm="."><plain>Cellular Activities of Selected Compounds in PC3M (Prostate) and U87MG (Glioblastoma) Human Tumour Cell Linesa </plain></SENT>
</text></title></caption><table-wrap-foot><fn id="t4fn1"><label>a</label><p><text><SENT sid="120" pm="."><plain>Inhibition of PKBβ kinase activity in a radiometric filter binding assay,(17) single determination. </plain></SENT>
<SENT sid="121" pm="."><plain>Standard inhibitor N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline sulfonamide (H-89) gave mean IC50 (±SD) = 590 (±220) nM (n = 20). </plain></SENT>
</text></p></fn><fn id="t4fn2"><label>b</label><p><text><SENT sid="122" pm="."><plain>Cell growth inhibition by sulforhodamine B colorimetric assay,(33) single determination in PC3 M human prostate cancer cells. </plain></SENT>
<SENT sid="123" pm="."><plain>Standard inhibitor H-89 gave mean (±SD) IC50 = 18 (±6.0) μM in this assay. </plain></SENT>
</text></p></fn><fn id="t4fn3"><label>c</label><p><text><SENT sid="124" pm="."><plain>Cellular ELISA for inhibition of GSK3β phosphorylation in PC3 M cells,(32) Standard inhibitor H-89 gave mean (±SD) IC50 = 15 (±2.0) μM. </plain></SENT>
</text></p></fn><fn id="t4fn4"><label>d</label><p><text><SENT sid="125" pm="."><plain>Cell growth inhibition by sulforhodamine B colorimetric assay,(32) single determination in U87MG human glioblastoma cancer cells. </plain></SENT>
<SENT sid="126" pm="."><plain>Standard inhibitor H-89 gave mean (±SD) IC50 = 15 (±2.3) μM in this assay. </plain></SENT>
</text></p></fn><fn id="t4fn5"><label>e</label><p><text><SENT sid="127" pm="."><plain>Cellular ELISA for inhibition of GSK3β phosphorylation in U87MG cells.(32) Standard inhibitor 2-(4-morpholino)-8-phenyl-4H-1-benzopyran-4-one (LY294002) gave IC50 = 8.1 (±3.0) μM. </plain></SENT>
</text></p></fn><fn id="t4fn6"><label>f</label><p><text><SENT sid="128" pm="."><plain>Mean of n = 2 determinations, individual values in parentheses. </plain></SENT>
</text></p></fn><fn id="t4fn7"><label>g</label><p><text><SENT sid="129" pm="."><plain>nd not determined. </plain></SENT>
</text></p></fn><fn id="t4fn8"><label>h</label><p><text><SENT sid="130" pm="."><plain>n = 2 determinations. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="131" pm="."><plain>The inhibitory effect of compounds 2, 10, and 21 toward five human cytochrome P450 isoforms (1A2, 2D6, 3A4, 2C9, and 2C19) was assessed in microsomal preparations.(34) In general, no significant inhibition was observed (IC50 &gt; 10 μM) for most of the isoforms tested. </plain></SENT>
<SENT sid="132" pm="."><plain>Compound 2 showed inhibition of the 2D6 isoform (IC50 = 0.66 μM), but this was not observed for compounds 10 and 21. </plain></SENT>
<SENT sid="133" pm="."><plain>Rather, these examples showed moderate inhibition (IC50 ca. </plain></SENT>
<SENT sid="134" pm="."><plain>1 μM) for the 2C9 isoform only. </plain></SENT>
</text></p><p><text><SENT sid="135" pm="."><plain>The pharmacokinetic properties of compounds from this series were investigated in mice, including the selective pyrrolo[2,3-d]pyrimidine inhibitors 2, 10, and 21 (Table 5). </plain></SENT>
<SENT sid="136" pm="."><plain>The 4-(4-tert-butylbenzyl)-4-aminopiperidine 10 showed a similar profile to that for 2.(17) Following iv dosing at 10 mg/kg, compound 10 was widely distributed but was very quickly cleared from the general circulation with a plasma clearance higher than that of mouse liver blood flow. </plain></SENT>
<SENT sid="137" pm="."><plain>Although compound 2 had shown low oral bioavailability (Foral = 8.5%), no measurable drug levels were detectable for 10 following oral dosing. </plain></SENT>
<SENT sid="138" pm="."><plain>Oxidative metabolites of 2 and 10, corresponding to masses of M + 16 and M + 32, were detected by mass spectrometry in plasma samples from these experiments. </plain></SENT>
<SENT sid="139" pm="."><plain>The fragmentation patterns in the mass spectra of the M + 16 metabolite of 2, when compared to those for the parent drug, suggested that oxidation was occurring at C-2 in the piperidine ring. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="tbl5" position="float"><label>Table 5</label><caption><title><text><SENT sid="140" pm="."><plain>Pharmacokinetic Parameters of Compounds 2, 10, and 21 in Mice </plain></SENT>
</text></title></caption><table-wrap-foot><fn id="t5fn1"><label>a</label><p><text><SENT sid="141" pm="."><plain>Pharmacokinetic parameters were calculated using the program WinNonLin, fitted to model 201 with default settings. </plain></SENT>
</text></p></fn><fn id="t5fn2"><label>b</label><p><text><SENT sid="142" pm="."><plain>Following oral administration of same dose. </plain></SENT>
</text></p></fn><fn id="t5fn3"><label>c</label><p><text><SENT sid="143" pm="."><plain>Plasma levels below limit of detection following oral dosing. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="144" pm="."><plain>A striking difference was observed in the in vivo pharmacokinetic properties of the inhibitors containing the 4-amino-4-amidopiperidine moiety, such as 21, compared to the 4-benzyl-4-aminopiperidines 2 and 10. </plain></SENT>
<SENT sid="145" pm="."><plain>The plasma clearance of 21 was approximately 3-fold lower than that of 2 and 10, while the volume of distribution was also reduced for the more polar amide scaffold. </plain></SENT>
<SENT sid="146" pm="."><plain>Importantly, compound 21 showed very good oral bioavailability in mice (Foral = 58%). </plain></SENT>
<SENT sid="147" pm="."><plain>While lower first pass metabolism and subsequent reduced clearance may contribute to the improved oral bioavailabilty of 21, the difference in basicity between 2 and 21 may also play a part. </plain></SENT>
<SENT sid="148" pm="."><plain>Calculated pKa values(35) for the protonation of the 4-amino group varied between 8.8 and 9.3 for 2, depending on the methodology, compared to a range of 6.5−7.4 for 21. </plain></SENT>
<SENT sid="149" pm="."><plain>Thus the 4-amino-4-amidopiperidines would be expected to be significantly less protonated than 2 or 10 in the gut, leading to enhanced passive absorption. </plain></SENT>
<SENT sid="150" pm="."><plain>The solubilities of 2 and 21 were determined in aqueous buffer at pH 7 and 6.5. </plain></SENT>
<SENT sid="151" pm="."><plain>Interestingly, the solubility of 2 showed a strong pH dependence, with S = 0.26 mg/mL at pH 6.5 but negligible solubility at pH 7, suggesting a much greater aqueous solubility for the protonated than the unprotonated form. </plain></SENT>
<SENT sid="152" pm="."><plain>In contrast, the solubilty of 21 was less affected by pH (S = 0.1 mg/mL at pH 7, S = 0.04 mg/mL at pH 6.5). </plain></SENT>
<SENT sid="153" pm="."><plain>Thus better solubility for the unprotonated form may also contribute to the improved bioavailability of 21. </plain></SENT>
</text></p><p><text><SENT sid="154" pm="."><plain>Earlier reported studies on the efficacy of some indazole-derived PKB inhibitors in human tumor xenograft models had suggested that mechanism-related effects of PKB inhibition could underlie the toxicity observed with these compounds.(12a) We were therefore keen to test selective inhibitors from the novel pyrrolo[2,3-d]pyrimidine series in vivo. </plain></SENT>
<SENT sid="155" pm="."><plain>The efficacy and pharmacodynamic effects of the orally bioavailable inhibitor 21 and the close analogue 32 were studied in mice bearing established subcutaneous U87MG human glioblastoma xenografts (Figure 4). </plain></SENT>
<SENT sid="156" pm="."><plain>Doses of 21 up to 200 mg kg−1 (5 days dosing in 7) were well tolerated with no effects on mouse body weight (not shown). </plain></SENT>
<SENT sid="157" pm="."><plain>Efficacy was measured by comparison of the estimated volume of tumors in treated and control groups during the study (Figure 4) and by comparison of the final tumor weights in the treated and control groups (T/C). </plain></SENT>
<SENT sid="158" pm="."><plain>Very strong inhibition of tumor growth was seen with T/C = 23%. </plain></SENT>
<SENT sid="159" pm="."><plain>Additionally, 44% of treated tumors had regressed in volume at the completion of the experiment. </plain></SENT>
<SENT sid="160" pm="."><plain>In a parallel pharmacokinetic and pharmacodynamic study, high levels of 21 were found in plasma and tumor samples (20 and 43 μM, respectively) at 4 h after a single dose. </plain></SENT>
<SENT sid="161" pm="."><plain>Clear inhibition of PKB signaling in the tumors was observed using an electrochemiluminescence immunoassay to measure levels of phospho-GSK3β in tumor lysates(32) (Figure 4). </plain></SENT>
<SENT sid="162" pm="."><plain>Thus despite the somewhat reduced cellular antiproliferative activity for the more polar scaffold of 21 compared to 2, the good tolerability and reduced clearance of 21 enabled oral dosing to achieve drug levels above the concentrations at which mechanism-based and antiproliferative effects were seen in vitro in cells, resulting in inhibition of the target in vivo and reduction of tumor growth. </plain></SENT>
<SENT sid="163" pm="."><plain>Measurement of tumor pharmacodynamic changes in other kinase-mediated pathways would be required to establish if inhibition of other targets can contribute to the efficacy of the compounds, however the selectivity profile of the compounds argues for a major contribution from PKB inhibition. </plain></SENT>
<SENT sid="164" pm="."><plain>Similar effects on in vivo biomarkers and reduction in growth (T/C = 32%) of U87MG tumor xenografts were seen following treatment with the closely related compound 32, also dosed orally at 200 mg/kg (Figure 4). </plain></SENT>
<SENT sid="165" pm="."><plain>Details of the efficacy, pharmacodynamic effects, and tumor pharmacokinetics of 21 (CCT129524) in a broader range of tumor xenograft models will be reported separately. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig4" position="float"><label>Figure 4</label><caption><p><text><SENT sid="166" pm="."><plain>Effect of 21 (A) and 32 (C) (both dosed at 200 mg/kg po 5 days per week) on the growth of U87MG human glioblastoma xenografts in CrTac:Ncr-Fox1(nu) athymic mice. </plain></SENT>
<SENT sid="167" pm="."><plain>Effect of 21 (B) and 32 (D) on PKB phosphorylation of GSK3β in U87MG human tumor xenografts at 4 h (B) or 6 h (D) following a single dose of 200 mg/kg po. </plain></SENT>
</text></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2009-01788j_0007" id="gr4" position="float"/></fig></SecTag></sec></SecTag><SecTag type="CONCL"><sec id="sec3"><title><text><SENT sid="168" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="169" pm="."><plain>A series of 4-benzyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amines provided potent inhibitors of PKBβ. </plain></SENT>
<SENT sid="170" pm="."><plain>The selectivity for inhibition of PKBβ over the closely related kinase PKA was increased by introducing larger lipophilic substituents to the benzyl group. </plain></SENT>
<SENT sid="171" pm="."><plain>This strategy exploited the subtly different binding modes for the ligands between the two targets, arising from a single amino acid residue difference within the ATP-binding site of the enzymes. </plain></SENT>
<SENT sid="172" pm="."><plain>The 4-amino-4-benzylpiperidine scaffold underwent metabolism in vivo, leading to rapid clearance and poor oral bioavailability. </plain></SENT>
<SENT sid="173" pm="."><plain>This was overcome by modification of the piperidine scaffold to give orally bioavailable 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides, exemplified by the potent and selective PKB inhibitor 21. </plain></SENT>
<SENT sid="174" pm="."><plain>Compound 21 showed good selectivity for inhibition of PKB over a range of other human kinases, with some activity observed for related AGC kinases. </plain></SENT>
<SENT sid="175" pm="."><plain>The observation of strong tumor growth inhibition and biomarker modulation in vivo with well tolerated doses of 21 supports the further evaluation of compounds from this series as potential anticancer therapeutics. </plain></SENT>
</text></p></sec></SecTag><sec id="sec4"><title><text><SENT sid="176" pm="."><plain>Experimental Section </plain></SENT>
</text></title><sec id="sec4.1"><title><text><SENT sid="177" pm="."><plain>Synthetic Chemistry </plain></SENT>
</text></title><p><text><SENT sid="178" pm="."><plain>Substituted 4-amino-4-benzylpiperidine intermediates were prepared from 4-cyano-4-benzylpiperidines as previously described for 2 using a Curtius rearrangement sequence to install the 4-amino substituent.(17) A more convenient reagent combination for this transformation was found by treating 4-benzyl-4-carbamoylpiperidines with bis(trifluoroacetoxy)iodobenzene,(36) as exemplified for the preparation of 10 (Scheme 1). </plain></SENT>
<SENT sid="179" pm="."><plain>Alternatively, the reactive tert-butyl sulfinimine formed from N-Boc-piperidin-4-one and tert-butylsulfonamide was reacted in situ with benzylic Grignard reagents to give the 4-amino-4-benzylpiperidine scaffolds directly.(37) Hinge-binding groups were introduced to the piperidines through SNAr reaction of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine, 6-chloro-7H-purin-8(9H)-one, or 4-fluoro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine,(38) which occurred selectively at the more reactive and less hindered secondary nitrogen atom. </plain></SENT>
<SENT sid="180" pm="."><plain>Additionally, the piperidines were reacted with ethyl 4-chloro-1H-pyrazolo[3,4-b]pyridine-5-carboxylate(39) followed by decarboxylation to give the pyrazolo[3,4-b]pyridine hinge-binder. </plain></SENT>
<SENT sid="181" pm="."><plain>Through these means the 4-benzyl-4-aminopiperidine analogues 2−18, 36, 37, 39, 40, 42, and 43 were prepared. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="sch1" position="float"><label>Scheme 1</label><caption><p><text><SENT sid="182" pm="."><plain> </plain></SENT>
</text></p><p id="sch1-fn1"><text><SENT sid="183" pm="."><plain>Reagents and conditions (yields for R = 4-tBu): (i) LDA, 4-tert-butylbenzyl bromide, THF, −78 °C, 79%; (ii) AcOH, H2SO4, reflux, then Boc2O, NaOH, dioxane-H2O, 71%; (iii) PhI(TFA)2, MeCN-H2O, 46%; (iv) tert-butylsulfinamide, Ti(OEt)4 (2 equiv), THF, reflux, then 4-tert-butylbenzylmagnesium bromide (5 equiv), THF, rt, 26%; (v) 4M HCl, dioxane, MeOH, rt, 100%; (vi) 4-chloro-7H-pyrrolo[2,3-d]pyrimidine, Et3N, n-BuOH, 100 °C, 86%; (vii) 4-fluoro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine, Et3N, NMP, 160 °C, 37%; (viii) 6-chloro-7H-purin-8(9H)-one, Et3N, n-BuOH 100 °C, 50%; (ix) ethyl 4-chloro-1H-pyrazolo[3,4-b]pyridine-5-carboxylate, Et3N, n-BuOH, 100 °C, 66%; (x) KOH, H2O, 120 °C, 47%. </plain></SENT>
</text></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2009-01788j_0008" id="gr5" position="float"/></fig></SecTag><p><text><SENT sid="184" pm="."><plain>To prepare the ether-linked analogue 19, 1-(tert-butoxycarbonyl)-4-(tert-butoxycarbonylamino)piperidine-4-carboxylic acid 47 was reduced to the alcohol 48 with lithium aluminum hydride and O-benzylated to give 49 after double N-deprotection (Scheme 2). </plain></SENT>
<SENT sid="185" pm="."><plain>The piperidine 49 was reacted with 4-chloro-7H-pyrrolo[2,3-d]pyrimidine to give the test compound 19. </plain></SENT>
<SENT sid="186" pm="."><plain>Alternatively, formation of the primary amide from 47 and reduction with borane in THF gave the 4-aminomethylpiperidine 50. </plain></SENT>
<SENT sid="187" pm="."><plain>Acylation with 4-chlorobenzoyl chloride and deprotection produced the amide 51, which was coupled to the pyrrolopyrimidine hinge-binder to give 20. </plain></SENT>
<SENT sid="188" pm="."><plain>The isomeric amide 21 was prepared from an initial coupling of 4-chlorobenzylamine and 47 to give the amide 52. </plain></SENT>
<SENT sid="189" pm="."><plain>Deprotection to 53 and introduction of the pyrrolopyrimidine gave 21. </plain></SENT>
<SENT sid="190" pm="."><plain>Analogues of 21 with different substitution of the amide were prepared by varying the amine in the first step of this sequence. </plain></SENT>
<SENT sid="191" pm="."><plain>The 4-carbamido-4-aminopiperidine 53 was reacted with 4-fluoro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine(38) and 6-chloro-7H-purin-8(9H)-one to give the analogues 38 and 41, respectively. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="sch2" position="float"><label>Scheme 2</label><caption><p><text><SENT sid="192" pm="."><plain> </plain></SENT>
</text></p><p id="sch2-fn1"><text><SENT sid="193" pm="."><plain>Reagents and conditions: (i) LiAlH4, THF, 0 °C then rt, 47%; (ii) NaH, 4-chlorobenzyl bromide, DMF, 0 °C then rt, 22%; (iii) 4M HCl, dioxane, MeOH, rt; 100%; (iv) 4-chloro-7H-pyrrolo[2,3-d]pyrimidine, Et3N, n-BuOH, 100 °C, 69−82%; (v) 1-hydroxybenzotriazole, 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide, DMF, NH3 aq, rt, 97%; (vi) BH3, THF, 0 °C then 60 °C, 6%; (vii) 4-chlorobenzoyl chloride, Et3N, CH2Cl2, rt, 35%; (viii) R1R2NH, HATU, iPr2NEt, DMF, rt, (R1R2NH = 4-chlorobenzylamine, 86%). </plain></SENT>
</text></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2009-01788j_0009" id="gr6" position="float"/></fig></SecTag></sec><sec id="sec4.2"><title><text><SENT sid="194" pm="."><plain>General Synthetic Chemistry </plain></SENT>
</text></title><p><text><SENT sid="195" pm="."><plain>Reactions were carried out under N2. </plain></SENT>
<SENT sid="196" pm="."><plain>Organic solutions were dried over MgSO4 or Na2SO4. </plain></SENT>
<SENT sid="197" pm="."><plain>Starting materials and solvents were purchased from commercial suppliers and were used without further purification. </plain></SENT>
<SENT sid="198" pm="."><plain>Microwave reactions were carried out using Biotage Initiator 60 or CEM microwave reactors. </plain></SENT>
<SENT sid="199" pm="."><plain>Flash silica chromatography was performed using Merck silica gel 60 (0.025−0.04 mm). </plain></SENT>
<SENT sid="200" pm="."><plain>Ion exchange chromatography was performed using Isolute Flash SCX-II (acidic) or Flash NH2 (basic) resin cartridges. 1H NMR spectra were recorded on a Bruker AMX500 instrument at 500 MHz using internal deuterium locks. 13C NMR spectra were recorded on a Bruker AMX500 instrument at 125 MHz. </plain></SENT>
<SENT sid="201" pm="."><plain>Chemical shifts (δ) are reported relative to TMS (δ = 0) and/or referenced to the solvent in which they were measured. </plain></SENT>
<SENT sid="202" pm="."><plain>Combined HPLC-MS analyses were recorded using a Waters Alliance 2795 separations module and Waters/Micromass LCT mass detector with electrospray ionization (+ve or −ve ion mode as indicated) and with HPLC performed using Supelco DISCOVERY C18, 50 mm × 4.6 mm or 30 mm × 4.6 mm i.d. columns, at a temperature of 22 °C with gradient elution of 10−90% MeOH/0.1% aqueous formic acid at a flow rate of 1 mL/min and a run time of 3.5 or 10 min as indicated. </plain></SENT>
<SENT sid="203" pm="."><plain>Compounds were detected at 254 nm using a Waters 2487 dual λ absorbance detector. </plain></SENT>
<SENT sid="204" pm="."><plain>All tested compounds gave &gt;95% purity as determined by this method. </plain></SENT>
<SENT sid="205" pm="."><plain>All purified synthetic intermediates gave &gt;95% purity as determined by this method except where indicated in the text. </plain></SENT>
<SENT sid="206" pm="."><plain>High-resolution mass spectra were measured on an Agilent 6210 ToF HPLC-MS with a Phenomenex Gemini 3 μm C18 (3 cm × 4.6 mm i.d.) column. </plain></SENT>
</text></p></sec><sec id="sec4.3"><title><text><SENT sid="207" pm="."><plain>General Methods for Preparation of 4-Amino-4-benzylpiperidines </plain></SENT>
</text></title><sec id="sec4.3.1"><title><text><SENT sid="208" pm="."><plain>4-(4-tert-Butylbenzyl)piperidin-4-amine (45) </plain></SENT>
</text></title><p><text><SENT sid="209" pm="."><plain>Method A. n-BuLi (2.32 M in hexanes, 11.8 mL, 27.4 mmol) was added to a solution of iPr2NH (3.8 mL, 27.4 mmol) in THF (75 mL) at −78 °C under N2. </plain></SENT>
<SENT sid="210" pm="."><plain>After 10 min, a solution of tert-butyl 4-cyanopiperidine-1-carboxylate (5.00 g, 23.8 mmol) in THF (30 mL) was added. </plain></SENT>
<SENT sid="211" pm="."><plain>The cloudy solution was stirred for 1 h at −78 °C. </plain></SENT>
<SENT sid="212" pm="."><plain>1-(Bromomethyl)-4-tert-butylbenzene (5.2 mL, 28.5 mmol) was added and the clear yellow−brown solution was warmed to rt and stirred for 15 h. </plain></SENT>
<SENT sid="213" pm="."><plain>Water (500 mL) was added, and the mixture was extracted with Et2O (2 × 250 mL). </plain></SENT>
<SENT sid="214" pm="."><plain>The organic layers were combined, washed with brine (200 mL), dried, and concentrated. </plain></SENT>
<SENT sid="215" pm="."><plain>Recrystallization from Et2O−hexane gave tert-butyl 4-(4-tert-butylbenzyl)-4-cyanopiperidine-1-carboxylate (6.69 g, 79%). </plain></SENT>
<SENT sid="216" pm="."><plain>LC-MS (3.5 min) m/z 379 [M + Na+], Rt = 2.96 min. 1H NMR (CDCl3) δ 1.33 (s, 9H), 1.47 (s, 9H), 1.48−1.52 (m, 2H), 2.85 (s, 2H), 2.95−3.04 (m, 2H), 4.08−4.16 (m, 2H), 7.20−7.22 (m, 2H), 7.36−7.38 (m, 2H). 13C NMR (CDCl3) δ 28.4, 31.3, 34.5, 34.7, 39.2, 41.0, 45.4, 80.0, 122.0, 125.4, 130.0, 131.2, 150.5, 154.5 ppm. </plain></SENT>
<SENT sid="217" pm="."><plain>A solution of tert-butyl 4-(4-tert-butylbenzyl)-4-cyanopiperidine-1-carboxylate (5.40 g, 15.2 mmol) in AcOH (14 mL) and conc H2SO4 (7 mL) was heated at 50 °C for 3 h and then at 90 °C for 2 h. </plain></SENT>
<SENT sid="218" pm="."><plain>The mixture was cooled and cautiously basified to pH 14 by the addition of 2 M NaOH aq (350 mL). </plain></SENT>
<SENT sid="219" pm="."><plain>Boc2O (4.96 g, 22.7 mmol) in dioxane (100 mL) was added, and the mixture was stirred for 24 h. </plain></SENT>
<SENT sid="220" pm="."><plain>The mixture was extracted with EtOAc (3 × 100 mL). </plain></SENT>
<SENT sid="221" pm="."><plain>The extracts were dried and concentrated. </plain></SENT>
<SENT sid="222" pm="."><plain>Flash column chromatography, eluting with EtOAc, gave tert-butyl 4-(4-tert-butylbenzyl)-4-carbamoylpiperidine-1-carboxylate 44 (4.02 g, 71%). </plain></SENT>
<SENT sid="223" pm="."><plain>LC-MS (3.5 min) m/z 397 [M + Na+], Rt = 2.86 min. 1H NMR (CDCl3) δ 1.31 (s, 9H), 1.46 (s, 9H), 1.49−1.56 (m, 2H), 2.81 (s, 2H), 3.00−3.07 (m, 2H), 3.82−3.90 (m, 2H), 7.07−7.08 (m, 2H), 7.29−7.30 (m, 2H). 13C NMR (CDCl3) δ 28.4, 31.3, 33.5, 34.4, 41.0 (br), 45.6, 46.7, 79.6, 125.1, 129.9, 133.1, 149.7, 154.9, 176.9 ppm. </plain></SENT>
</text></p><p><text><SENT sid="224" pm="."><plain>Bis(trifluoroacetoxy)iodobenzene (5.05 g, 11.8 mmol) was added to a suspension of 44 (4.00 g, 10.7 mmol) in MeCN (17 mL) and water (17 mL). </plain></SENT>
<SENT sid="225" pm="."><plain>After 17 h, water (70 mL) and conc HCl (15 mL) were added. </plain></SENT>
<SENT sid="226" pm="."><plain>After a further 1 h, the mixture was washed with Et2O (100 mL) and the aqueous layer was concentrated to give 4-(4-tert-butylbenzyl)piperidin-4-amine bis hydrochloride 45 (1.57 g, 46%). </plain></SENT>
<SENT sid="227" pm="."><plain>LC-MS (10 min) m/z 247 [M + H+], Rt = 1.25 min. 1H NMR (CD3OD) δ 1.33 (s, 9H), 2.14−2.17 (m, 4H), 3.16 (s, 2H), 3.47−3.49 (m, 4H), 7.24−7.26 (m, 2H), 7.47−7.49 (m, 2H). 13C NMR (CD3OD) δ 30.9, 31.7, 35.4, 40.7, 41.7, 54.5, 127.2, 131.2, 131.7, 152.2 ppm. </plain></SENT>
</text></p><p><text><SENT sid="228" pm="."><plain>Method B. </plain></SENT>
<SENT sid="229" pm="."><plain>Ti(OEt)4 (0.42 mL, 2.00 mmol) was added to a solution of tert-butyl 4-oxopiperidine-1-carboxylate (0.205 g, 1.03 mmol) and 2-methylpropane-2-sulfinamide (0.130 g, 1.07 mmol) in THF (5 mL) at rt. </plain></SENT>
<SENT sid="230" pm="."><plain>The resulting pale-yellow solution was refluxed for 5 h and then cooled to 0 °C. </plain></SENT>
<SENT sid="231" pm="."><plain>A solution of (4-tert-butylbenzyl)magnesium bromide in Et2O, prepared from Mg (0.121 g, 5.00 mmol), 4-tert-butylbenzyl bromide (0.62 mL, 5.00 mmol), and Et2O (5 mL), was added and the mixture was stirred at rt for 15 h. </plain></SENT>
<SENT sid="232" pm="."><plain>The reaction was quenched with methanol (5 mL) and absorbed onto silica gel. </plain></SENT>
<SENT sid="233" pm="."><plain>Flash column chromatography, eluting with EtOAc−hexanes 1:1, gave tert-butyl 4-(4-tert-butylbenzyl)-4-(1,1-dimethylethylsulfinamido)piperidine-1-carboxylate 46 (0.121 g, 26%). </plain></SENT>
<SENT sid="234" pm="."><plain>LC-MS (10 min) m/z 473 [M + Na+], Rt = 8.84 min. 1H NMR (CDCl3) δ 7.32−7.28 (m, 4H), 3.90−3.71 (br m, 2H), 3.35 (br s, 1H), 3.17 (d, J = 13.5 Hz, 1H), 3.15−2.98 (br m, 2H), 2.68 17 (d, J = 13.5 Hz, 1H), 2.36−2.33 (m, 1H), 1.79−1.72 (m, 1H), 1.59−1.54 (m, 1H), 1.46 (s, 9H), 1.42−1.35 (m, 1H), 1.32 (s, 9H), 1.25 (s, 9H). </plain></SENT>
<SENT sid="235" pm="."><plain>4 M HCl in dioxane (4 mL) was added to 46 (0.111 g, 0.246 mmol) in MeOH (4 mL) at rt. </plain></SENT>
<SENT sid="236" pm="."><plain>After 16 h, the mixture was concentrated and purified by ion exchange on acidic resin, eluting with MeOH and then 2 M NH3 in MeOH to give 45 (free amine) (0.061 g, 100%). </plain></SENT>
<SENT sid="237" pm="."><plain>LC-MS (10 min) m/z 247 [M + H+], Rt = 1.25 min. 1H NMR (CD3OD) δ 1.33 (s, 9H), 1.39−1.41 (m, 2H), 1.60−1.65 (m, 2H), 2.71 (s, 2H), 2.85−2.96 (m, 4H), 7.14−7.15 (m, 2H), 7.34−7.36 (m, 2H). 13C NMR (CD3OD) δ 31.8, 35.2, 39.1, 43.0, 47.8, 50.9, 126.0, 131.5, 131.7, 135.4, 150.8 ppm. </plain></SENT>
</text></p></sec></sec><sec id="sec4.4"><title><text><SENT sid="238" pm="."><plain>General Method for Preparation of Pyrrolo[2,3-d]pyrimidines </plain></SENT>
</text></title><sec id="sec4.4.1"><title><text><SENT sid="239" pm="."><plain>4-(4-tert-Butylbenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine (10) </plain></SENT>
</text></title><p><text><SENT sid="240" pm="."><plain>A mixture of 45 bis hydrochloride salt (0.500 g, 1.57 mmol), 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (0.229 g, 1.49 mmol) and Et3N (1.04 mL, 7.46 mmol) in n-BuOH (15 mL) was heated at 100 °C for 20 h. </plain></SENT>
<SENT sid="241" pm="."><plain>The mixture was cooled, concentrated, and the resulting solid washed with CH2Cl2 (15 mL). </plain></SENT>
<SENT sid="242" pm="."><plain>The residual solid was collected. </plain></SENT>
<SENT sid="243" pm="."><plain>Ion exchange chromatography on acidic resin, eluting with MeOHand then 2 M NH3 in MeOH, gave 10 (0.465 g, 86%). </plain></SENT>
<SENT sid="244" pm="."><plain>LC-MS (10 min) m/z 364 [M + H+], Rt = 4.25 min. </plain></SENT>
<SENT sid="245" pm="."><plain>Hi-Res LC-MS calcd for C22H30N5 364.2501, found 364.2503. 1H NMR (CD3OD) δ 1.32 (s, 9H), 1.55−1.58 (m, 2H), 1.75−1.81 (m, 2H), 2.78 (s, 2H), 3.79−3.85 (m, 2H), 4.24−4.29 (m, 2H), 6.63 (d, J = 4.0 Hz, 1H), 7.13 (d, J = 4.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 8.12 (s, 1H). 13C NMR (CD3OD) 31.9, 35.3, 38.2, 43.3, 51.4, 102.7, 104.2, 122.2, 126.2, 131.6, 135.0, 150.6, 151.7, 152.4, 158.3 ppm. </plain></SENT>
<SENT sid="246" pm="."><plain>One 13C peak was obscured by solvent. </plain></SENT>
</text></p></sec><sec id="sec4.4.2"><title><text><SENT sid="247" pm="."><plain>4-Amino-N-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (21) </plain></SENT>
</text></title><p><text><SENT sid="248" pm="."><plain>Dry DMF (1 mL) was added to a mixture of 47 (151 mg, 0.44 mmol) and HATU (220 mg, 0.58 mmol). iPr2NEt (0.38 mL, 2.1 mmol) was added, and the mixture was stirred for 15 min at rt. </plain></SENT>
<SENT sid="249" pm="."><plain>4-Chloro-benzylamine (70 μL, 0.57 mmol) was added, and the solution was stirred for 23 h. </plain></SENT>
<SENT sid="250" pm="."><plain>The reaction mixture was partitioned between water (10 mL) and CH2Cl2 (3 × 10 mL). </plain></SENT>
<SENT sid="251" pm="."><plain>The organic extracts were dried, filtered, and concentrated. </plain></SENT>
<SENT sid="252" pm="."><plain>Flash column chromatography, eluting with CH2Cl2−MeOH 96:4, gave 4-tert-butoxycarbonylamino-4-(4-chloro-benzylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester 52 (177 mg, 0.38 mmol, 86%). </plain></SENT>
<SENT sid="253" pm="."><plain>LC-MS (10 min) m/z 490 [M + Na+], Rt = 8.07 min. 1H NMR (CDCl3) δ 1.41 (s, 9H), 1.47 (s, 9H), 1.98 (br d, J = 12 Hz, 2H), 2.10−2.16 (m, 2H), 3.10−3.15 (m, 2H), 3.84 (b rd, J = 11 Hz, 2H), 4.42 (d, J = 5 Hz, 2H), 4.69 (s, 1H), 7.22 (d, J = 9 Hz, 2H), 7.28 (d, J = 9 Hz, 2H). 13C NMR (CDCl3) δ 28.2, 28.4, 32.2, 39.9, 42.9, 57.7, 79.8, 80.9, 128.7, 128.9, 133.2, 136.9, 154.6, 154.9, 173.4 ppm. </plain></SENT>
</text></p><p><text><SENT sid="254" pm="."><plain>HCl (4 M) in dioxane (4.8 mL, 19.2 mmol) was added dropwise to a solution of 52 (96 mg, 0.20 mmol) in MeOH (4.8 mL). </plain></SENT>
<SENT sid="255" pm="."><plain>The solution was stirred at rt for 17 h. </plain></SENT>
<SENT sid="256" pm="."><plain>The mixture was concentrated to give 4-amino-piperidine-4-carboxylic acid 4-chloro-benzylamide bis hydrochloride 53 (70 mg, 0.20 mmol, 100%) that was used in the next step without further purification. 1H NMR (CD3OD) δ 2.15−2.22 (m, 2H), 2.60−2.69 (m, 2H), 3.34−3.36 (m, 2H), 3.44−3.46 (m, 2H), 4.47 (s, 2H), 7.36 (s, 4H). 13C NMR (CD3OD) δ 29.6, 41.0, 44.2, 57.5, 129.7, 130.6, 134.4, 138.3, 169.4 ppm. </plain></SENT>
<SENT sid="257" pm="."><plain>A degassed mixture of 53 bis hydrochloride (48 mg, 0.14 mmol), 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (21 mg, 0.12 mmol), Et3N (126 μL, 0.9 mmol), and n-BuOH (1.2 mL) was stirred at 100 °C for 18 h. </plain></SENT>
<SENT sid="258" pm="."><plain>The mixture was concentrated and purified by ion exchange chromatography on acidic resin, eluting with MeOH then 2 M NH3 in MeOH. </plain></SENT>
<SENT sid="259" pm="."><plain>Preparative TLC, eluting with CH2Cl2−MeOH 9:1, gave 21 (37 mg, 0.096 mmol, 69%). </plain></SENT>
<SENT sid="260" pm="."><plain>LC-MS (10 min) m/z 385 [M + H+], Rt = 2.88 min. </plain></SENT>
<SENT sid="261" pm="."><plain>Hi Res LC-MS calcd for C19H22N6OCl 385.1544, found 385.1557. 1H NMR (CD3OD) δ 1.61 (br d, J = 14 Hz, 2H), 2.19−2.25 (m, 2H), 3.65−3.71 (m, 2H), 4.38 (s, 2H), 4.47−4.50 (m, 2H), 6.64 (d, J = 4 Hz, 1H), 7.14 (d, J = 4 Hz, 1H), 7.28 (d, J = 8 Hz, 2H), 7.32 (d, J = 8 Hz, 2H), 8.14 (s, 1H). 13C NMR (CD3OD) δ 35.6, 43.0, 43.4, 57.2, 102.5, 104.2, 122.4, 129.6, 130.0, 133.9, 139.1, 151.6, 152.4, 158.2, 179.4 ppm. </plain></SENT>
</text></p></sec></sec></sec></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="262" pm="."><plain>We thank Dr A. </plain></SENT>
<SENT sid="263" pm="."><plain>Mirza, Dr M. </plain></SENT>
<SENT sid="264" pm="."><plain>Liu, and M. </plain></SENT>
<SENT sid="265" pm="."><plain>Richards for assistance in the spectroscopic characterisation of test compounds and V. </plain></SENT>
<SENT sid="266" pm="."><plain>Martins for assistance in analysing PK parameters. </plain></SENT>
<SENT sid="267" pm="."><plain>This work was supported by funding from Cancer Research UK [CUK] grant numbers C309/A2187, C309/A8274, and C309/A8365, and The Institute of Cancer Research. </plain></SENT>
<SENT sid="268" pm="."><plain>We acknowledge NHS funding to the NIHR Biomedical Research Centre. </plain></SENT>
<SENT sid="269" pm="."><plain>This work was carried out as part of a funded research collaboration with Astex Therapeutics and intellectual property arising from the programme has been licensed to AstraZeneca plc. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="SUPPL"><notes id="notes-1" notes-type="si"><title>Supporting Information Available</title><p>Representative experimental procedures and characterization data for compounds <bold>3</bold>−<bold>9</bold>, <bold>11</bold>−<bold>20</bold>, <bold>22</bold>−<bold>43</bold>; kinase panel selectivity data for compounds <bold>10</bold> and <bold>21</bold>; experimental procedures for PKBβ and PKA biochemical assays; experimental procedures for SRB and ELISA cellular assays; details of the X-ray crystallography data collection and refinement for <bold>10</bold>-PKB, <bold>21</bold>-PKB. This material is available free of charge via the Internet at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://pubs.acs.org">http://pubs.acs.org</uri>.</p></notes></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm901788j_si_001.pdf"><caption><p><text><SENT sid="270" pm="."><plain>jm901788j_si_001.pdf </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="ref1"><text><SENT sid="271" pm="."><plain>SaleE. </plain></SENT>
<SENT sid="272" pm="."><plain>M.; SaleG. </plain></SENT>
<SENT sid="273" pm="."><plain>J. Protein kinase B: signalling roles and therapeutic target. Cell. </plain></SENT>
<SENT sid="274" pm="."><plain>Mol. </plain></SENT>
<SENT sid="275" pm="."><plain>Life Sci. 2008, 65, 113–127.17952368 </plain></SENT>
</text></ref><ref id="ref2"><text><SENT sid="276" pm="."><plain>CarneroA.; Blanco-AparicioC.; RennerO.; LinkW.; LealJ. </plain></SENT>
<SENT sid="277" pm="."><plain>F. </plain></SENT>
<SENT sid="278" pm="."><plain>M. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic application. Curr. </plain></SENT>
<SENT sid="279" pm="."><plain>Cancer Drug Targets 2008, 8, 187–198.18473732 </plain></SENT>
</text></ref><ref id="ref3"><text><SENT sid="280" pm="."><plain>MilburnC. </plain></SENT>
<SENT sid="281" pm="."><plain>C.; DeakM.; KellyS. </plain></SENT>
<SENT sid="282" pm="."><plain>M.; PriceN. </plain></SENT>
<SENT sid="283" pm="."><plain>C.; AlessiD. </plain></SENT>
<SENT sid="284" pm="."><plain>R.; Van AaltenD. </plain></SENT>
<SENT sid="285" pm="."><plain>M. </plain></SENT>
<SENT sid="286" pm="."><plain>F. Binding of phoisphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem. </plain></SENT>
<SENT sid="287" pm="."><plain>J. 2003, 375, 531–538.12964941 </plain></SENT>
</text></ref><ref id="ref4"><text><SENT sid="288" pm="."><plain>SarbassovD. </plain></SENT>
<SENT sid="289" pm="."><plain>D.; GuertinD. </plain></SENT>
<SENT sid="290" pm="."><plain>A.; AliS. </plain></SENT>
<SENT sid="291" pm="."><plain>M.; SabatiniD. </plain></SENT>
<SENT sid="292" pm="."><plain>M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307, 1098–1101.15718470 </plain></SENT>
</text></ref><ref id="ref5"><text><SENT sid="293" pm="."><plain>YapT. </plain></SENT>
<SENT sid="294" pm="."><plain>A.; GarrettM. </plain></SENT>
<SENT sid="295" pm="."><plain>D.; WaltonM. </plain></SENT>
<SENT sid="296" pm="."><plain>I.; RaynaudF.; De BonoJ. </plain></SENT>
<SENT sid="297" pm="."><plain>S.; WorkmanP. Targeting the PI3K−AKT−mTOR pathway: progress, pitfalls, and promises. Curr. </plain></SENT>
<SENT sid="298" pm="."><plain>Opin. </plain></SENT>
<SENT sid="299" pm="."><plain>Pharmacol. 2008, 8, 393–412.18721898 </plain></SENT>
</text></ref><ref id="ref6"><text><SENT sid="300" pm="."><plain>BellacosaA.; KumarC. </plain></SENT>
<SENT sid="301" pm="."><plain>C.; Di CristofanoA.; TestaJ. </plain></SENT>
<SENT sid="302" pm="."><plain>R. Activation of AKT kinases in cancer: implications for cancer therapeutics. Adv. </plain></SENT>
<SENT sid="303" pm="."><plain>Cancer Res. 2005, 94, 29–86.16095999 </plain></SENT>
</text></ref><ref id="ref7"><text><SENT sid="304" pm="."><plain>LindsleyC. </plain></SENT>
<SENT sid="305" pm="."><plain>W.; BarnettS. </plain></SENT>
<SENT sid="306" pm="."><plain>F.; YaroschakM.; BilodeauM. </plain></SENT>
<SENT sid="307" pm="."><plain>T. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr. </plain></SENT>
<SENT sid="308" pm="."><plain>Top. </plain></SENT>
<SENT sid="309" pm="."><plain>Med. </plain></SENT>
<SENT sid="310" pm="."><plain>Chem. 2007, 7, 1349–1363.17692025 </plain></SENT>
</text></ref><ref id="ref8"><text><SENT sid="311" pm="."><plain>LindsleyC. </plain></SENT>
<SENT sid="312" pm="."><plain>W.; BarnettS. </plain></SENT>
<SENT sid="313" pm="."><plain>F.; LaytonM. </plain></SENT>
<SENT sid="314" pm="."><plain>E.; BilodeauM. </plain></SENT>
<SENT sid="315" pm="."><plain>T. The PI3/Akt Pathway: Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr. </plain></SENT>
<SENT sid="316" pm="."><plain>Cancer Drug Targets 2008, 8, 7–18.18288939 </plain></SENT>
</text></ref><ref id="ref9"><text><SENT sid="317" pm="."><plain>LiQ. Recent progress in the discovery of Akt inhibitors as anticancer agents. Expert Opin. </plain></SENT>
<SENT sid="318" pm="."><plain>Ther. </plain></SENT>
<SENT sid="319" pm="."><plain>Patents 2007, 17, 1077–1130. </plain></SENT>
</text></ref><ref id="ref10"><text><SENT sid="320" pm="."><plain>CollinsI. Targeted small molecule inhibitors of protein kinase B as anticancer agents. Anti-Cancer Agents Med. </plain></SENT>
<SENT sid="321" pm="."><plain>Chem. 2009, 9, 32–50. </plain></SENT>
</text></ref><ref id="ref11"><text><SENT sid="322" pm="."><plain>aLuoY.; ShoemakerA. </plain></SENT>
<SENT sid="323" pm="."><plain>R.; LiuX.; WoodsK. </plain></SENT>
<SENT sid="324" pm="."><plain>W.; ThomasS. </plain></SENT>
<SENT sid="325" pm="."><plain>A.; de JongR.; HanE. </plain></SENT>
<SENT sid="326" pm="."><plain>K.; LiT.; StollV. </plain></SENT>
<SENT sid="327" pm="."><plain>S.; PowlasJ. </plain></SENT>
<SENT sid="328" pm="."><plain>A.; OleksijewA.; MittenM. </plain></SENT>
<SENT sid="329" pm="."><plain>J.; ShiY.; GuanR.; McGonigalT. </plain></SENT>
<SENT sid="330" pm="."><plain>P.; KlinghoferV.; JohnsonE. </plain></SENT>
<SENT sid="331" pm="."><plain>F.; LeversonJ. </plain></SENT>
<SENT sid="332" pm="."><plain>D.; BouskaJ. </plain></SENT>
<SENT sid="333" pm="."><plain>J.; MamoM.; SmithR. </plain></SENT>
<SENT sid="334" pm="."><plain>A.; Gramling-EvansE. </plain></SENT>
<SENT sid="335" pm="."><plain>E.; ZinkerB. </plain></SENT>
<SENT sid="336" pm="."><plain>A.; MikaA. </plain></SENT>
<SENT sid="337" pm="."><plain>K.; NguyenP. </plain></SENT>
<SENT sid="338" pm="."><plain>T.; OltersdorfT.; RosenbergS. </plain></SENT>
<SENT sid="339" pm="."><plain>H.; LiQ.; GirandaV. </plain></SENT>
<SENT sid="340" pm="."><plain>L. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. </plain></SENT>
<SENT sid="341" pm="."><plain>Cancer Ther. 2005, 4, 977–986.15956255bWoodsK. </plain></SENT>
<SENT sid="342" pm="."><plain>W.; FischerJ. </plain></SENT>
<SENT sid="343" pm="."><plain>P.; ClaiborneA.; LiT.; ThomasS. </plain></SENT>
<SENT sid="344" pm="."><plain>A.; ZhuG.; DieboldR. </plain></SENT>
<SENT sid="345" pm="."><plain>B.; LiuX.; ShiY.; KlinghoferV.; HanE. </plain></SENT>
<SENT sid="346" pm="."><plain>K.; GuanR.; MagnoneS. </plain></SENT>
<SENT sid="347" pm="."><plain>R.; JohnsonE. </plain></SENT>
<SENT sid="348" pm="."><plain>F.; BouskaJ. </plain></SENT>
<SENT sid="349" pm="."><plain>J.; OlsonA. </plain></SENT>
<SENT sid="350" pm="."><plain>M.; de JongR.; OltersdorfT.; LuoY.; RosenbergS. </plain></SENT>
<SENT sid="351" pm="."><plain>H.; GirandaV. </plain></SENT>
<SENT sid="352" pm="."><plain>L.; LiQ. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors. Bioorg. </plain></SENT>
<SENT sid="353" pm="."><plain>Med. </plain></SENT>
<SENT sid="354" pm="."><plain>Chem. 2006, 14, 6832–6846.16843670cLiQ; WoodsK. </plain></SENT>
<SENT sid="355" pm="."><plain>W.; ThomasS.; ZhuG. </plain></SENT>
<SENT sid="356" pm="."><plain>D.; PackardG.; FisherJ.; LiT.; GongJ.; DingesJ.; SongX.; AbramsJ.; LuoY.; JohnsonE. </plain></SENT>
<SENT sid="357" pm="."><plain>F.; ShiY.; LiuX.; KlinghoferV.; Des JongR.; OltersdorfT.; StollV. </plain></SENT>
<SENT sid="358" pm="."><plain>S.; JakobC. </plain></SENT>
<SENT sid="359" pm="."><plain>G.; RosenbergS. </plain></SENT>
<SENT sid="360" pm="."><plain>H.; GirandaV. </plain></SENT>
<SENT sid="361" pm="."><plain>L. Synthesis and structure−activity relationship of 3,4′-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer. Bioorg. </plain></SENT>
<SENT sid="362" pm="."><plain>Med. </plain></SENT>
<SENT sid="363" pm="."><plain>Chem. </plain></SENT>
<SENT sid="364" pm="."><plain>Lett. 2006, 16, 2000–2007.16413780dZhuG. </plain></SENT>
<SENT sid="365" pm="."><plain>D.; GongJ.; ClaiborneA.; WoodsK. </plain></SENT>
<SENT sid="366" pm="."><plain>W.; GandhiV. </plain></SENT>
<SENT sid="367" pm="."><plain>B.; ThomasS.; LuoY.; LiuX.; ShiY.; GuanR.; MagnoneS. </plain></SENT>
<SENT sid="368" pm="."><plain>R.; KlinghoferV.; JohnsonE. </plain></SENT>
<SENT sid="369" pm="."><plain>F.; BouskaJ.; ShoemakerA.; OleksijewA.; StollV. </plain></SENT>
<SENT sid="370" pm="."><plain>S.; De JongR.; OltersdorfT.; LiQ.; RosenbergS. </plain></SENT>
<SENT sid="371" pm="."><plain>H.; GirandaV. </plain></SENT>
<SENT sid="372" pm="."><plain>L. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity. Bioorg. </plain></SENT>
<SENT sid="373" pm="."><plain>Med. </plain></SENT>
<SENT sid="374" pm="."><plain>Chem. </plain></SENT>
<SENT sid="375" pm="."><plain>Lett. 2006, 16, 3150–3155.16603355eZhuG. </plain></SENT>
<SENT sid="376" pm="."><plain>D.; GandhiV. </plain></SENT>
<SENT sid="377" pm="."><plain>B.; GongJ.; LuoY.; LiuX.; ShiY.; GuanR.; MagnoneS. </plain></SENT>
<SENT sid="378" pm="."><plain>R.; KlinghoferV.; JohnsonE. </plain></SENT>
<SENT sid="379" pm="."><plain>F.; BouskaJ.; ShoemakerA.; OleksijewA.; JarvisK.; ParkC.; JongR. </plain></SENT>
<SENT sid="380" pm="."><plain>D.; OltersdorfT.; LiQ.; RosenbergS. </plain></SENT>
<SENT sid="381" pm="."><plain>H.; GirandaV. </plain></SENT>
<SENT sid="382" pm="."><plain>L. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers. Bioorg. </plain></SENT>
<SENT sid="383" pm="."><plain>Med. </plain></SENT>
<SENT sid="384" pm="."><plain>Chem. </plain></SENT>
<SENT sid="385" pm="."><plain>Lett. 2006, 16, 3424–3429.16644221fThomasS. </plain></SENT>
<SENT sid="386" pm="."><plain>A.; LiT.; WoodsK. </plain></SENT>
<SENT sid="387" pm="."><plain>W.; SongX.; PackardG.; FischerJ. </plain></SENT>
<SENT sid="388" pm="."><plain>P.; DieboldR. </plain></SENT>
<SENT sid="389" pm="."><plain>B.; LiuX.; ShiY.; KlinghoferV.; JohnsonE. </plain></SENT>
<SENT sid="390" pm="."><plain>F.; BouskaJ. </plain></SENT>
<SENT sid="391" pm="."><plain>J.; OlsonA.; GuanR.; MagnoneS. </plain></SENT>
<SENT sid="392" pm="."><plain>R.; MarshK.; LuoY.; RosenbergS. </plain></SENT>
<SENT sid="393" pm="."><plain>H.; GirandaV. </plain></SENT>
<SENT sid="394" pm="."><plain>L.; LiQ. Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase. Bioorg. </plain></SENT>
<SENT sid="395" pm="."><plain>Med. </plain></SENT>
<SENT sid="396" pm="."><plain>Chem. </plain></SENT>
<SENT sid="397" pm="."><plain>Lett. 2006, 16, 3740–3704.16678413gZhuG. </plain></SENT>
<SENT sid="398" pm="."><plain>D.; GongJ.; GandhiV. </plain></SENT>
<SENT sid="399" pm="."><plain>B.; WoodsK.; LuoY.; LiuX.; GuanR.; KlinghoferV.; JohnsonE. </plain></SENT>
<SENT sid="400" pm="."><plain>F.; StollV. </plain></SENT>
<SENT sid="401" pm="."><plain>S.; MamoM.; LiQ.; RosenbergS. </plain></SENT>
<SENT sid="402" pm="."><plain>H.; GirandaV. </plain></SENT>
<SENT sid="403" pm="."><plain>L. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt. Bioorg. </plain></SENT>
<SENT sid="404" pm="."><plain>Med. </plain></SENT>
<SENT sid="405" pm="."><plain>Chem. 2007, 15, 2441–2452.17258463hZhuG. </plain></SENT>
<SENT sid="406" pm="."><plain>D.; GandhiV. </plain></SENT>
<SENT sid="407" pm="."><plain>B.; GongJ.; ThomasS.; WoodsK. </plain></SENT>
<SENT sid="408" pm="."><plain>W.; SongX.; LiT.; DieboldR. </plain></SENT>
<SENT sid="409" pm="."><plain>B.; LuoY.; LiuX.; GuanR.; KlinghoferV.; JohnsonE. </plain></SENT>
<SENT sid="410" pm="."><plain>F.; BouskaJ.; OlsonA.; MarshK. </plain></SENT>
<SENT sid="411" pm="."><plain>C.; StollV. </plain></SENT>
<SENT sid="412" pm="."><plain>S.; MamoM.; PolakowskiJ.; CampbellT. </plain></SENT>
<SENT sid="413" pm="."><plain>J.; MartinR. </plain></SENT>
<SENT sid="414" pm="."><plain>L.; GintantG. </plain></SENT>
<SENT sid="415" pm="."><plain>A.; PenningT. </plain></SENT>
<SENT sid="416" pm="."><plain>D.; LiQ.; RosenbergS. </plain></SENT>
<SENT sid="417" pm="."><plain>H.; GirandaV. </plain></SENT>
<SENT sid="418" pm="."><plain>L. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. J. </plain></SENT>
<SENT sid="419" pm="."><plain>Med. </plain></SENT>
<SENT sid="420" pm="."><plain>Chem. 2007, 50, 2990–3003.17523610 </plain></SENT>
</text></ref><ref id="ref12"><text><SENT sid="421" pm="."><plain>aBreitenlechnerC. </plain></SENT>
<SENT sid="422" pm="."><plain>B.; WeggeT.; BerillonL.; GraulK.; MarzenellK.; FriebeW. </plain></SENT>
<SENT sid="423" pm="."><plain>G.; ThomasU.; SchumacherR.; HuberR.; EnghR. </plain></SENT>
<SENT sid="424" pm="."><plain>A.; MasjostB. Structure-based optimization of novel azepane derivatives as PKB inhibitors. J. </plain></SENT>
<SENT sid="425" pm="."><plain>Med. </plain></SENT>
<SENT sid="426" pm="."><plain>Chem. 2004, 47, 1375–1390.14998327bBreitenlechnerC. </plain></SENT>
<SENT sid="427" pm="."><plain>B.; FriebeW. </plain></SENT>
<SENT sid="428" pm="."><plain>G.; BrunetE.; WernerG.; GraulK.; ThomasU.; KunkeleK. </plain></SENT>
<SENT sid="429" pm="."><plain>P.; SchaferW.; GasselM.; BossemeyerD.; HuberR.; EnghR. </plain></SENT>
<SENT sid="430" pm="."><plain>A.; MasjostB. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. J. </plain></SENT>
<SENT sid="431" pm="."><plain>Med. </plain></SENT>
<SENT sid="432" pm="."><plain>Chem. 2005, 48, 163–170.15634010 </plain></SENT>
</text></ref><ref id="ref13"><text><SENT sid="433" pm="."><plain>KoJ. </plain></SENT>
<SENT sid="434" pm="."><plain>H.; YeonS. </plain></SENT>
<SENT sid="435" pm="."><plain>W.; RyuJ. </plain></SENT>
<SENT sid="436" pm="."><plain>S.; KimT. </plain></SENT>
<SENT sid="437" pm="."><plain>Y.; SongE. </plain></SENT>
<SENT sid="438" pm="."><plain>H.; YouH. </plain></SENT>
<SENT sid="439" pm="."><plain>J.; ParkR. </plain></SENT>
<SENT sid="440" pm="."><plain>E.; RyuC. </plain></SENT>
<SENT sid="441" pm="."><plain>K. Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt. Bioorg. </plain></SENT>
<SENT sid="442" pm="."><plain>Med. </plain></SENT>
<SENT sid="443" pm="."><plain>Chem. </plain></SENT>
<SENT sid="444" pm="."><plain>Lett. 2006, 16, 6001–6005.16990001 </plain></SENT>
</text></ref><ref id="ref14"><text><SENT sid="445" pm="."><plain>aCollinsI.; CaldwellJ.; FonsecaT.; DonaldA.; BavetsiasV.; RowlandsM. </plain></SENT>
<SENT sid="446" pm="."><plain>G.; HunterL.-J. </plain></SENT>
<SENT sid="447" pm="."><plain>K.; GarrettM. </plain></SENT>
<SENT sid="448" pm="."><plain>D.; DaviesT. </plain></SENT>
<SENT sid="449" pm="."><plain>G.; BerdiniV.; WoodheadS.; DavisD.; SeaversL. </plain></SENT>
<SENT sid="450" pm="."><plain>C. </plain></SENT>
<SENT sid="451" pm="."><plain>A.; WyattP. </plain></SENT>
<SENT sid="452" pm="."><plain>G.; McDonaldE. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Bioorg. </plain></SENT>
<SENT sid="453" pm="."><plain>Med. </plain></SENT>
<SENT sid="454" pm="."><plain>Chem. 2006, 14, 1255–1273.16249095bReuveniH.; LivnahN.; GeigerT.; KleinS.; OhneO.; CohenI.; BenharM.; GellermanG.; LevitskiA. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 2002, 41, 10304–10314.12162746 </plain></SENT>
</text></ref><ref id="ref15"><text><SENT sid="455" pm="."><plain>DonaldA.; McHardyT.; RowlandsM. </plain></SENT>
<SENT sid="456" pm="."><plain>G.; HunterL-J. </plain></SENT>
<SENT sid="457" pm="."><plain>K.; DaviesT. </plain></SENT>
<SENT sid="458" pm="."><plain>G.; BerdiniV.; BoyleR. </plain></SENT>
<SENT sid="459" pm="."><plain>G.; AherneG. </plain></SENT>
<SENT sid="460" pm="."><plain>W.; GarrettM. </plain></SENT>
<SENT sid="461" pm="."><plain>D.; CollinsI. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. J. </plain></SENT>
<SENT sid="462" pm="."><plain>Med. </plain></SENT>
<SENT sid="463" pm="."><plain>Chem. 2007, 50, 2289–2292.17451235 </plain></SENT>
</text></ref><ref id="ref16"><text><SENT sid="464" pm="."><plain>SaxtyG.; WoodheadS. </plain></SENT>
<SENT sid="465" pm="."><plain>J.; BerdiniV.; DaviesT. </plain></SENT>
<SENT sid="466" pm="."><plain>G.; VerdonkM. </plain></SENT>
<SENT sid="467" pm="."><plain>L.; WyattP. </plain></SENT>
<SENT sid="468" pm="."><plain>G.; BoyleR. </plain></SENT>
<SENT sid="469" pm="."><plain>G.; BarfordD.; DownhamR.; GarrettM. </plain></SENT>
<SENT sid="470" pm="."><plain>D.; CarrR. </plain></SENT>
<SENT sid="471" pm="."><plain>A. Identification of novel inhibitors of protein kinase B using fragment-based lead discovery. J. </plain></SENT>
<SENT sid="472" pm="."><plain>Med. </plain></SENT>
<SENT sid="473" pm="."><plain>Chem. 2007, 50, 2293–2296.17451234 </plain></SENT>
</text></ref><ref id="ref17"><text><SENT sid="474" pm="."><plain>CaldwellJ. </plain></SENT>
<SENT sid="475" pm="."><plain>J.; DaviesT. </plain></SENT>
<SENT sid="476" pm="."><plain>G.; DonaldA.; McHardyT.; RowlandsM. </plain></SENT>
<SENT sid="477" pm="."><plain>G.; AherneG. </plain></SENT>
<SENT sid="478" pm="."><plain>W.; HunterL. </plain></SENT>
<SENT sid="479" pm="."><plain>K.; TaylorK.; RuddleR.; RaynaudF. </plain></SENT>
<SENT sid="480" pm="."><plain>I.; VerdonkM.; WorkmanP.; GarretM.; CollinsI. Identification of 4-(4-Aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration. J. </plain></SENT>
<SENT sid="481" pm="."><plain>Med. </plain></SENT>
<SENT sid="482" pm="."><plain>Chem. 2008, 51, 2147–2157.18345609 </plain></SENT>
</text></ref><ref id="ref18"><text><SENT sid="483" pm="."><plain>LippaB.; PanG.; CorbettM.; LiC.; KauffmanG. </plain></SENT>
<SENT sid="484" pm="."><plain>S.; PanditJ.; RobinsonS.; WeiL.; KozinaE.; MarrE. </plain></SENT>
<SENT sid="485" pm="."><plain>S.; BorzilloG.; KnauthE.; Barbacci-TobinE. </plain></SENT>
<SENT sid="486" pm="."><plain>G.; VincentP.; TroutmanM.; BakerD.; RajamohanF.; KakarS.; ClarkT.; MorrisJ. Synthesis and structure based optimization of novel Akt inhibitors. Bioorg. </plain></SENT>
<SENT sid="487" pm="."><plain>Med. </plain></SENT>
<SENT sid="488" pm="."><plain>Chem. </plain></SENT>
<SENT sid="489" pm="."><plain>Lett. 2008, 18, 3359–3363.18456494 </plain></SENT>
</text></ref><ref id="ref19"><text><SENT sid="490" pm="."><plain>aLinX.; MurrayJ. </plain></SENT>
<SENT sid="491" pm="."><plain>M.; RicoA. </plain></SENT>
<SENT sid="492" pm="."><plain>C.; WangM. </plain></SENT>
<SENT sid="493" pm="."><plain>X.; ChuD. </plain></SENT>
<SENT sid="494" pm="."><plain>T.; ZhouY.; Del RosarioM.; KaufmanS.; MaS.; FangE.; CrawfordK.; JeffersonA. </plain></SENT>
<SENT sid="495" pm="."><plain>B. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies. Bioorg. </plain></SENT>
<SENT sid="496" pm="."><plain>Med. </plain></SENT>
<SENT sid="497" pm="."><plain>Chem. </plain></SENT>
<SENT sid="498" pm="."><plain>Lett. 2006, 16, 4163–4168.16765046bSeefeldM. </plain></SENT>
<SENT sid="499" pm="."><plain>A.; RouseM. </plain></SENT>
<SENT sid="500" pm="."><plain>B.; McNultyK. </plain></SENT>
<SENT sid="501" pm="."><plain>C.; SunL.; WangJ.; YamashitaD. </plain></SENT>
<SENT sid="502" pm="."><plain>S.; LuengoJ. </plain></SENT>
<SENT sid="503" pm="."><plain>I.; ZhangS.; MinthornE. </plain></SENT>
<SENT sid="504" pm="."><plain>A.; ConchaN. </plain></SENT>
<SENT sid="505" pm="."><plain>O.; HeerdingD. </plain></SENT>
<SENT sid="506" pm="."><plain>A. Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors. Bioorg. </plain></SENT>
<SENT sid="507" pm="."><plain>Med. </plain></SENT>
<SENT sid="508" pm="."><plain>Chem. </plain></SENT>
<SENT sid="509" pm="."><plain>Lett. 2009, 19 (8), 2244–2248.19285393 </plain></SENT>
</text></ref><ref id="ref20"><text><SENT sid="510" pm="."><plain>RouseM. </plain></SENT>
<SENT sid="511" pm="."><plain>B.; SeefeldM. </plain></SENT>
<SENT sid="512" pm="."><plain>A.; LeberJ. </plain></SENT>
<SENT sid="513" pm="."><plain>D.; McNultyK. </plain></SENT>
<SENT sid="514" pm="."><plain>C.; SunL.; MillerW. </plain></SENT>
<SENT sid="515" pm="."><plain>H.; ZhangS.; MinthornE. </plain></SENT>
<SENT sid="516" pm="."><plain>A.; ConchaN. </plain></SENT>
<SENT sid="517" pm="."><plain>O.; ChoudhryA. </plain></SENT>
<SENT sid="518" pm="."><plain>E.; SchaberM. </plain></SENT>
<SENT sid="519" pm="."><plain>D.; HeerdingD. </plain></SENT>
<SENT sid="520" pm="."><plain>A. Aminofurazans as potent inhibitors of AKT kinase. Bioorg. </plain></SENT>
<SENT sid="521" pm="."><plain>Med. </plain></SENT>
<SENT sid="522" pm="."><plain>Chem. </plain></SENT>
<SENT sid="523" pm="."><plain>Lett. 2009, 19 (5), 1508–1511.19179070 </plain></SENT>
</text></ref><ref id="ref21"><text><SENT sid="524" pm="."><plain>HeerdingD. </plain></SENT>
<SENT sid="525" pm="."><plain>A.; RhodesN.; LeberJ. </plain></SENT>
<SENT sid="526" pm="."><plain>D.; ClarkT. </plain></SENT>
<SENT sid="527" pm="."><plain>J.; KeenanR. </plain></SENT>
<SENT sid="528" pm="."><plain>M.; LafranceL. </plain></SENT>
<SENT sid="529" pm="."><plain>V.; LiM.; SafonovI. </plain></SENT>
<SENT sid="530" pm="."><plain>G.; TakataD. </plain></SENT>
<SENT sid="531" pm="."><plain>T.; VenslavskyJ. </plain></SENT>
<SENT sid="532" pm="."><plain>W.; YamashitaD. </plain></SENT>
<SENT sid="533" pm="."><plain>S.; ChoudhryA. </plain></SENT>
<SENT sid="534" pm="."><plain>E.; CopelandR. </plain></SENT>
<SENT sid="535" pm="."><plain>A.; LaiZ.; SchaberM. </plain></SENT>
<SENT sid="536" pm="."><plain>D.; TumminoP. </plain></SENT>
<SENT sid="537" pm="."><plain>J.; StrumS. </plain></SENT>
<SENT sid="538" pm="."><plain>L.; WoodE. </plain></SENT>
<SENT sid="539" pm="."><plain>R.; DuckettD. </plain></SENT>
<SENT sid="540" pm="."><plain>R.; EberweinD.; KnickV. </plain></SENT>
<SENT sid="541" pm="."><plain>B.; LansingT. </plain></SENT>
<SENT sid="542" pm="."><plain>J.; McConnellR. </plain></SENT>
<SENT sid="543" pm="."><plain>T.; ZhangS.; MinthornE. </plain></SENT>
<SENT sid="544" pm="."><plain>A.; ConchaN. </plain></SENT>
<SENT sid="545" pm="."><plain>O.; WarrenG. </plain></SENT>
<SENT sid="546" pm="."><plain>L.; KumarR. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl] oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J. </plain></SENT>
<SENT sid="547" pm="."><plain>Med. </plain></SENT>
<SENT sid="548" pm="."><plain>Chem. 2008, 51, 5663–5679.18800763 </plain></SENT>
</text></ref><ref id="ref22"><text><SENT sid="549" pm="."><plain>CofferP. </plain></SENT>
<SENT sid="550" pm="."><plain>J.; WoodgettJ. </plain></SENT>
<SENT sid="551" pm="."><plain>R. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur. </plain></SENT>
<SENT sid="552" pm="."><plain>J. </plain></SENT>
<SENT sid="553" pm="."><plain>Biochem. 1991, 201, 475–481.1718748 </plain></SENT>
</text></ref><ref id="ref23"><text><SENT sid="554" pm="."><plain>LindsleyC. </plain></SENT>
<SENT sid="555" pm="."><plain>W.; ZhaoZ.; LeisterW. </plain></SENT>
<SENT sid="556" pm="."><plain>H.; RobinsonR. </plain></SENT>
<SENT sid="557" pm="."><plain>G.; BarnettS. </plain></SENT>
<SENT sid="558" pm="."><plain>F.; Defeo-JonesD.; JonesR. </plain></SENT>
<SENT sid="559" pm="."><plain>E.; HartmenG. </plain></SENT>
<SENT sid="560" pm="."><plain>D.; HuffJ. </plain></SENT>
<SENT sid="561" pm="."><plain>R.; HuberH. </plain></SENT>
<SENT sid="562" pm="."><plain>E.; DugganM. </plain></SENT>
<SENT sid="563" pm="."><plain>E. Allosteric Akt (PKB) inhibitors: discovery and SAR of isoenzyme specificity. Bioorg. </plain></SENT>
<SENT sid="564" pm="."><plain>Med. </plain></SENT>
<SENT sid="565" pm="."><plain>Chem. </plain></SENT>
<SENT sid="566" pm="."><plain>Lett. 2005, 15, 761–764.15664853 </plain></SENT>
</text></ref><ref id="ref24"><text><SENT sid="567" pm="."><plain>BarnettS. </plain></SENT>
<SENT sid="568" pm="."><plain>F.; Defeo-JonesD.; FuS.; HancockP. </plain></SENT>
<SENT sid="569" pm="."><plain>J.; HaskellK. </plain></SENT>
<SENT sid="570" pm="."><plain>M.; JonesR. </plain></SENT>
<SENT sid="571" pm="."><plain>E.; KahanaJ. </plain></SENT>
<SENT sid="572" pm="."><plain>A.; KralA. </plain></SENT>
<SENT sid="573" pm="."><plain>M.; LeanderK.; LeeL. </plain></SENT>
<SENT sid="574" pm="."><plain>L.; MalinowskiJ.; McAvoyE. </plain></SENT>
<SENT sid="575" pm="."><plain>M.; NahasD. </plain></SENT>
<SENT sid="576" pm="."><plain>D.; RobinsonR. </plain></SENT>
<SENT sid="577" pm="."><plain>G.; HuberH. </plain></SENT>
<SENT sid="578" pm="."><plain>E. Identification and characterisation of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. </plain></SENT>
<SENT sid="579" pm="."><plain>J. 2005, 385, 399–408.15456405 </plain></SENT>
</text></ref><ref id="ref25"><text><SENT sid="580" pm="."><plain>TolcherA. </plain></SENT>
<SENT sid="581" pm="."><plain>W.; YapT. </plain></SENT>
<SENT sid="582" pm="."><plain>A.; FearenI.; TaylorA.; CarpenterC.; BrunettoA. </plain></SENT>
<SENT sid="583" pm="."><plain>T.; BeeramM.; PapadopoulosK.; YanL.; de BonoJ.A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J. </plain></SENT>
<SENT sid="584" pm="."><plain>Clin. </plain></SENT>
<SENT sid="585" pm="."><plain>Oncol.2009, 27 (15s), (Suppl. abstr 3503) (Abstract of presentation at ASCO, American Society of Clinical Oncologists, 2009 Annual Meeting, May 29-Jun 2, Orlando, FL). </plain></SENT>
</text></ref><ref id="ref26"><text><SENT sid="586" pm="."><plain>DaviesT. </plain></SENT>
<SENT sid="587" pm="."><plain>G.; VerdonkM. </plain></SENT>
<SENT sid="588" pm="."><plain>L.; GrahamB.; Saalau-BethellS.; HamlettC. </plain></SENT>
<SENT sid="589" pm="."><plain>C.; McHardyT.; CollinsI.; GarrettM. </plain></SENT>
<SENT sid="590" pm="."><plain>D.; WorkmanP.; WoodheadS. </plain></SENT>
<SENT sid="591" pm="."><plain>J.; JhotiH.; BarfordD. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J. </plain></SENT>
<SENT sid="592" pm="."><plain>Mol. </plain></SENT>
<SENT sid="593" pm="."><plain>Biol. 2007, 367, 882–894.17275837 </plain></SENT>
</text></ref><ref id="ref27"><text><SENT sid="594" pm="."><plain>Kinase selectivity was determined in the SelectScreen assay, Invitrogen Ltd. </plain></SENT>
<SENT sid="595" pm="."><plain>Compounds were tested at 1 μM, with [ATP] = 10 μM, against the following enzymes: CDK2/cyclinA, CHK1, CHK2, CK2α1, EGFR, FGFR1, FLT3, GSK3β, IGFR1, JAK3, KDR, MAPK1, MAPKAPK2, PKA, PKCα, PKCδ, PKCγ, ROCK2, RSK2, p70S6K, SGK1, SRC. </plain></SENT>
</text></ref><ref id="ref28"><text><SENT sid="596" pm="."><plain>GraczykP. </plain></SENT>
<SENT sid="597" pm="."><plain>P. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. J. </plain></SENT>
<SENT sid="598" pm="."><plain>Med. </plain></SENT>
<SENT sid="599" pm="."><plain>Chem. 2007, 50, 5773–5779.17948979 </plain></SENT>
</text></ref><ref id="ref29"><text><SENT sid="600" pm="."><plain>ManningG.; WhyteD. </plain></SENT>
<SENT sid="601" pm="."><plain>B.; MartinezR.; HunterT.; SudarsanamS.The protein kinase complement of the human genome. Science2002, 298 (5600), 1912−1916, 1933−1934.12471243 </plain></SENT>
</text></ref><ref id="ref30"><text><SENT sid="602" pm="."><plain>VlietstraR. </plain></SENT>
<SENT sid="603" pm="."><plain>J.; van AlewijkD. </plain></SENT>
<SENT sid="604" pm="."><plain>C.; HermansK. </plain></SENT>
<SENT sid="605" pm="."><plain>G.; van SteenbruggeG. </plain></SENT>
<SENT sid="606" pm="."><plain>J.; TrapmanJ. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998, 58, 2720–2723.9661880 </plain></SENT>
</text></ref><ref id="ref31"><text><SENT sid="607" pm="."><plain>RaynaudF. </plain></SENT>
<SENT sid="608" pm="."><plain>I.; EcclesS.; ClarkeP. </plain></SENT>
<SENT sid="609" pm="."><plain>A.; HayesA.; NutleyB.; AlixS.; HenleyA.; Di-StefanoF.; AhmadZ.; GuillardS.; BjerkeL. </plain></SENT>
<SENT sid="610" pm="."><plain>M.; KellandL.; ValentiM.; PattersonL.; GowanS.; de Haven BrandonA.; HayakawaM.; KaizawaH.; KoizumiT.; OhishiT.; PatelS.; SaghirN.; ParkerP.; WaterfieldM.; WorkmanP. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 2007, 67, 5840–5850.17575152 </plain></SENT>
</text></ref><ref id="ref32"><text><SENT sid="611" pm="."><plain>GowanS. </plain></SENT>
<SENT sid="612" pm="."><plain>M.; HardcastleA.; HallsworthA. </plain></SENT>
<SENT sid="613" pm="."><plain>E.; ValentiM. </plain></SENT>
<SENT sid="614" pm="."><plain>R.; HunterL.-J. </plain></SENT>
<SENT sid="615" pm="."><plain>K.; de Haven BrandonA. </plain></SENT>
<SENT sid="616" pm="."><plain>K.; GarrettM. </plain></SENT>
<SENT sid="617" pm="."><plain>D.; RaynaudF.; WorkmanP.; AherneW.; EcclesS. </plain></SENT>
<SENT sid="618" pm="."><plain>A. Application of mesoscale technology for the measurement of phospho-proteins in human tumour xenografts. Assay Drug Dev. </plain></SENT>
<SENT sid="619" pm="."><plain>Technol. 2007, 5, 391–401.17638539 </plain></SENT>
</text></ref><ref id="ref33"><text><SENT sid="620" pm="."><plain>SkehanP.; StorengR.; ScudieroD.; MonksA.; McMahonJ.; VisticaD.; WarrenJ. </plain></SENT>
<SENT sid="621" pm="."><plain>T.; BokeschH.; KenneyS.; BoydM. </plain></SENT>
<SENT sid="622" pm="."><plain>R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. </plain></SENT>
<SENT sid="623" pm="."><plain>Natl. </plain></SENT>
<SENT sid="624" pm="."><plain>Cancer Inst. 1990, 82, 1107–1112.2359136 </plain></SENT>
</text></ref><ref id="ref34"><text><SENT sid="625" pm="."><plain>Moreno-FarreJ.; WorkmanP.; RaynaudF. </plain></SENT>
<SENT sid="626" pm="."><plain>I. Analysis of potential drug−drug interactions for anticancer agents in human liver microsomes by high throughput liquid chromatography/mass spectrometry assay. Recent Adv. </plain></SENT>
<SENT sid="627" pm="."><plain>Res. </plain></SENT>
<SENT sid="628" pm="."><plain>Updates 2006, 7, 207–224. </plain></SENT>
</text></ref><ref id="ref35"><text><SENT sid="629" pm="."><plain>aSaidS. </plain></SENT>
<SENT sid="630" pm="."><plain>H.; KarickhoffS. </plain></SENT>
<SENT sid="631" pm="."><plain>W.; CarreiraL. </plain></SENT>
<SENT sid="632" pm="."><plain>A. A rigorous test for SPARC's chemical reactivity models: estimation of more than 4300 ionization pKa's. Quant. </plain></SENT>
<SENT sid="633" pm="."><plain>Struct. </plain></SENT>
<SENT sid="634" pm="."><plain>Act. </plain></SENT>
<SENT sid="635" pm="."><plain>Rel. 1995, 14, 348–355.bMillettiF.; StorchiL.; SfornaG.; CrucianiG. New and original pKa prediction method using grid molecular interaction fields. J. </plain></SENT>
<SENT sid="636" pm="."><plain>Chem. </plain></SENT>
<SENT sid="637" pm="."><plain>Inf. </plain></SENT>
<SENT sid="638" pm="."><plain>Model. 2007, 47, 2172–2181.17910431 </plain></SENT>
</text></ref><ref id="ref36"><text><SENT sid="639" pm="."><plain>PallaiP; GoodmanM. Preparation of optically pure monoacyl 2-alkyl gem-diamines from peptide amides. J. </plain></SENT>
<SENT sid="640" pm="."><plain>Chem. </plain></SENT>
<SENT sid="641" pm="."><plain>Soc., Chem. </plain></SENT>
<SENT sid="642" pm="."><plain>Commun. 1982, 280–281. </plain></SENT>
</text></ref><ref id="ref37"><text><SENT sid="643" pm="."><plain>CaldwellJ. </plain></SENT>
<SENT sid="644" pm="."><plain>J.; CollinsI. Rapid synthesis of 4-benzyl-4-aminopiperidines by addition of Grignard reagents to N-(1-Boc-piperidin-4-ylidene)-tert-butanesulfinyl imine. Synlett 2006, 2565–2568. </plain></SENT>
</text></ref><ref id="ref38"><text><SENT sid="645" pm="."><plain>CaldwellJ. </plain></SENT>
<SENT sid="646" pm="."><plain>J.; CheungK. </plain></SENT>
<SENT sid="647" pm="."><plain>M.; CollinsI. Synthesis of 4-(cyclic dialkylamino)-7-azaindoles by microwave heating of 4-halo-7-azaindoles and cyclic secondary amines. Tetrahedron Lett. 2007, 48, 1527–1529. </plain></SENT>
</text></ref><ref id="ref39"><text><SENT sid="648" pm="."><plain>aMatthewsT. </plain></SENT>
<SENT sid="649" pm="."><plain>P.; KlairS.; BurnsS.; BoxallK.; CherryM.; FisherM.; WestwoodI. </plain></SENT>
<SENT sid="650" pm="."><plain>M.; WaltonM. </plain></SENT>
<SENT sid="651" pm="."><plain>I.; McHardyT.; CheungK.-M. </plain></SENT>
<SENT sid="652" pm="."><plain>J.; Van MontfortR.; WilliamsD.; AherneG. </plain></SENT>
<SENT sid="653" pm="."><plain>W.; GarrettM. </plain></SENT>
<SENT sid="654" pm="."><plain>D.; ReaderJ.; CollinsI. Identification of Inhibitors of Checkpoint Kinase 1 through Template Screening. J. </plain></SENT>
<SENT sid="655" pm="."><plain>Med. </plain></SENT>
<SENT sid="656" pm="."><plain>Chem. 2009, 52, 4810–4819.19572549bHoehnH.; DenzelT.1H-Pyrazolo[3,4-b]pyridines. Patent Appl. </plain></SENT>
<SENT sid="657" pm="."><plain>DE2301268. Chem. </plain></SENT>
<SENT sid="658" pm="."><plain>Abs.1973, 79, 115578. </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
